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ABSTRACT 
The organocatalytic, direct vinylogous aldol reaction (ODVA) of 2-furanone (-
crotonolactone) is of interest because the reaction provides direct access to γ-substituted 
butenolides, an important structural motif in several natural products and biologically 
active compounds. We have observed that this reaction is catalyzed by chiral 
aminothioureas and aminosquaramides. A detailed investigation of this method is 
described in Chapter 2. The ODVA reaction of γ-crotonolactone with aldehydes can be 
used for the synthesis of substance P receptor antagonist piperidines (+)-L-733,060 and 
(+)-CP-99,994, and also for the synthesis of (2S,3R)-3-hydroxypipecolic acid, which is a 
component of tetrazomine, an antitumor agent and an antibiotic. These results are 
presented in Chapter 3. This methodology is also useful for the total synthesis of the 
antimalarial alkaloid (+)-febrifugine and a formal synthesis of (+)-halofuginone, an 
antimalarial agent. The results of this work are described in Chapter 4. 
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CHAPTER 1 
Introduction 
 
The aldol reaction is one of the most powerful synthetic tools in organic 
chemistry for carbon-carbon bond formation. Within the domain of aldol processes, the 
vinylogous extension is of considerable interest. In 1935, R. C. Fuson introduced the 
principle of vinylogy
1
 to explain the effect of a functional group at a position in the 
molecule that is separated from the functional group by a double bond. This concept 
allows for the transmission of electronic effects through a conjugated π-system of a 
carbon–carbon double bond. This “vinylogous extension” has been applied to the aldol 
reaction by employing α,β-unsaturated carbonyl compounds as the nucleophilic 
component (Scheme 1.1).
2a 
 
 
Scheme 1.1. Classical aldol vs. vinylogous aldol reactions. 
 
Over the years, the vinylogous aldol reactions of silyloxy dienes (vinylogous 
Mukaiyama aldol reaction) as the nucleophiles have been thoroughly studied. Most of the 
3 
 
vinylogous Mukaiyama aldol (VMA) reactions use metal-based catalysts, with several 
reviews available on this topic.
2
 In recent years the use of non-metal-derived catalysts 
(boron derived catalysts and bisphosphoramide/SiCl4 catalysts) and organocatalysts 
(metal-free organic catalysts) for the VMA reaction has proven to be successful. There 
are a few reviews available for the non-metal-derived catalysis,
2a,3
 as well as the 
organocatalytic version.
4
 In terms of atom economy, the organocatalytic direct 
vinylogous aldol (ODVA) reaction, which uses unmodified aldehydes and ketones as 
nucleophiles, is the most attractive version even though this strategy can be limited by 
regioselectivity issues associated with the dienolate nucleophiles.
5
               
         
 
1.1 The organocatalytic vinylogous Mukaiyama aldol (OVMA) reaction 
The interest in OVMA reactions is mainly due to the products being of great 
importance in natural product synthesis.
2,3a
 With this backdrop, ample research efforts 
have been directed towards the development of efficient organocatalysts for asymmetric 
vinylogous aldol reactions. The OVMA reactions can be classified into two groups: 1) 
OVMA reactions of cyclic silyloxydienes, and 2) OVMA reactions of acyclic 
silyloxydienes. 
 
1.1.1 OVMA reactions of cyclic siloxydienes 
Rawal and co-workers
6
 reported the first example of an organocatalyzed addition 
of siloxydiene 6 (Scheme 1.2) to aldehydes using various alkaloids and chiral diols as 
catalysts. Preliminary studies with 2-nitrobenzaldehyde as the electrophile identified the 
4 
 
tartrate-derived TADDOL 8 (α,α,α’,α’-tetraaryl-1,3-dioxolane-4,5-dimethanol) as a 
promising catalyst. Thus, under optimized conditions, the siloxydiene 6 reacts with a 
variety of aldehydes in presence of a catalytic amount of TADDOL 8 to provide the 
vinylogous aldol adducts 9 (Scheme 1.2) in poor to good yields (23-73%) and 
enantioselectivity (22-90% ee). In general, aromatic aldehydes gave better results than 
aliphatic aldehydes in terms of yield and enantioslectectivity. Also, all of the reactions 
showed complete γ-selectivity. 
 
 
Scheme 1.2. The first asymmetric OVMA reactions catalyzed by TADDOL. 
 
Complementary to the TADDOL catalyzed process, Scettri and Acocella
7
 
reported the VMA reaction of siloxydiene 10 catalyzed by a Lewis base (Scheme 1.3). 
Initial experiments with the diene 10 and 4-methylbenzaldehyde indicated that pyridine 
N-oxide is the catalyst of choice among other catalysts such as dimethyl sulfoxide 
(DMSO), dimethylformamide (DMF) and hexamethylphosphoramide (HMPA). A variety 
of aromatic aldehydes provided the aldol adduct 12 in moderate yields. The asymmetric 
version of this reaction was not investigated in this study. 
5 
 
 
Scheme 1.3. The Lewis base catalyzed OVMA reaction reported by Scettri and Acocella. 
Zanardi and Casiraghi
8
 have developed a novel variant of the classical Lewis acid 
catalyzed vinylogous Mukaiyama aldol reaction using tert-butyl 2-[(tert-
butyldimethylsilyl)oxy]-1H-pyrrole-1-carboxylate 13 as the conjugate donor. 
Subsequently, the organocatalytic version of their reaction catalyzed by various ureas and 
thioureas was reported by Soriente.
9
 By using 13 as the vinylogous donor, structurally 
and stereochemically diverse γ-substituted-α,β-unsaturated lactam silyl ethers were 
obtained in high yields (Scheme 1.4). Optimization studies revealed that the urea 14 was 
the catalyst of choice and the OVMA reaction provided a mixture of anti (15a) and syn 
(15b) aldol products in poor to good yields. The asymmetric version of this reaction was 
not investigated in this study.  
 
Scheme 1.4. The OVMA reaction of 13 by urea catalyst 14. 
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The OVMA reactions of siloxyfurans 16 as nucleophiles were first reported by 
Soriente
10
 in 2006. Several aromatic aldehydes were examined for the VMA reaction 
using 1,3-bis-(3,5-(trifluoromethyl)phenyl)urea 17 (10 mol%) as catalyst at room 
temperature and the γ-butenolide adducts were obtained in poor to good yields (Scheme 
1.5). The diastereoselectivity of the reaction was moderate (1.9:1 to 1:1), favoring the 
anti diastereomer in some cases. 
 
 
Scheme 1.5. Diarylureas as catalysts for the OVMA reaction of trimethylsiloxyfuran. 
 
The same group reported the OVMA reaction of 2-(silyloxy)furan with aromatic 
as well as aliphatic aldehydes using calixpyrrole
11
 derivatives as catalysts. Calixpyrroles 
are known for their ability to bind anions and neutral molecules by multiple hydrogen-
bonding interactions with the pyrrole NH functionality. A number of calixpyrroles were 
tested as catalysts, but these reactions resulted in low to moderate yields (15-70%) and 
moderate diastereoselectivities (2.3-4:1). 
The first enantioselective version of the OVMA reaction of a 2-(silyloxy)furan 
with a variety of aldehydes was reported by Mukaiyama and co-workers.
12
 This protocol 
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relies on the cinchonidine-derived quaternary ammonium phenoxide 20 as the 
organocatalyst (Scheme 1.6). Preliminary studies with trimethylsiloxyfuran and all 
isomers of methyl-2-(trimethylsiloxy)furan as nucleophiles showed that 4-methyl-2-
(trimethylsiloxy)furan 19 is the best nucleophile in terms of yield, diastereoselectivity 
and enantioselectivity. Reactions with a series of aromatic and a few aliphatic aldehydes 
were examined. These reactions proceeded with poor to excellent diastereoselectivies 
(2:1 to 99:1), and  the enantioselectivities of these reactions were moderate to excellent 
(57-97% ee). 
 
Scheme 1.6. Enantioselective OVMA reactions catalyzed by cinchonidine salt 20. 
 
Deng et al.
13
 examined cinchona alkaloid salts as catalysts for the OVMA 
reaction of 2-(silyloxy)furan with various aldehydes (Scheme 1.7). The salt of quinine 
derived thiourea with trifluoroacetate 22 was identified as the catalyst of choice. The 
reaction was anti selective, and both aromatic, as well as aliphatic aldehydes gave 
8 
 
moderate to excellent yields (47-98%). In general, the diastereoselectivities and 
enantioselectivities with aromatic aldehydes (4.2:1 to 24:1 d.r.; 86-95 % ee) were much 
better than those observed with aliphatic aldehydes (2.5:1 to 4.5:1 d.r.; 80-93% ee). 
 
 
Scheme 1.7. OVMA reaction catalyzed by quinine derived aminothiourea salt. 
 
In a related study, Wang and co-workers
14
 have developed an asymmetric OVMA 
reaction of 2-(silyloxy)furan with aldehydes in the presence of a quinine-derived catalyst 
(free base of 22). The results of this study are similar to those obtained by Deng et al. 
These reactions are conducted in chloroform at -20 
o
C. In general, the 
diastereoselectivities and enantioselectivities (1.5:1 to 9:1 d.r.; 84-91% ee) were similar 
to those obtained with the trifluoroacetate salt 22.  
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1.1.2 OVMA reactions of acyclic siloxydienes 
So far, the use of acyclic siloxydienes as nucleophiles in the VMA reaction under 
organocatalytic conditions has been less explored. Only a few examples are known using 
acyclic siloxydienes as nucleophiles. Villano and Scettri
15
 have utilized Chan’s diene 2316 
as the vinylogous donor. In this study, several aromatic aldehydes were used to provide 
the vinylogous aldol product 25 (Scheme 1.8). Notably, all these reactions proceeded 
with complete γ-selectivity. Interestingly, in the case of electron-poor aldehydes the 
chiral pyran-4-ones 26 were also obtained, along with the expected VMA adduct 25. The 
authors suggest that 26 is obtained by a hetero-Diels-Alder reaction of the diene and the 
aldehyde. 
 
 
Scheme 1.8. The OVMA reaction catalyzed by TADDOL. 
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List et al.
17
 developed an improved OVMA reaction using a variety of 
disulfonimides as catalysts. The diene 27 reacted with a variety of aldehydes to generate 
aldol products 29 in a highly regioselective (γ/α > 40:1) manner (Scheme 1.9). 
 
Scheme 1.9. Disulfonimide catalyzed OVMA reaction. 
 
In addition to the vinylogous aldol reaction, the bisvinylogous mode
17
 of the 
reaction was also investigated (Scheme 1.10). These were the first examples of 
organocatalytic bisvinylogous aldol reactions, which proceeded with good 
enantioselectivity (up to 92% ee). The ε-product 31 was obtained with an all E 
configuration. Many aldehydes were tested and the optimized reaction conditions were 
particularly suitable for aromatic and cinnamaldehydes. Most interestingly, the γ-adducts 
were not detected in any of the reactions. 
11 
 
 
Scheme 1.10. Disulfonimide catalyzed bisvinylogous aldol reaction. 
 
1.2 Organocatalytic direct vinylogous aldol (ODVA) reaction 
The organocatalytic direct vinylogous aldol (ODVA) reaction is a more attractive 
version in terms of atom economy.
2
 There are several challenges in controlling 
diastereoselectivity, enantioselectivity, chemoselectivity and regioselectivity associated 
with these reactions. So far, ODVA reactions are less explored and only a few studies 
have examined the application of unmodified α,β-unsaturated aldehydes as nucleophiles. 
 
1.2.1 ODVA reactions of acyclic dienes  
Bräse and coworkers
18
 reported an ODVA reaction of salicylaldehyde 32 and 
senecialdehyde 33, employing DABCO as the catalyst (Scheme 1.11). The tricyclic 
hemiacetal 34 was obtained by initial deprotonation of the senecialdehyde 33 at the γ-
methyl group followed by the vinylogous aldol reaction of the resulting dienolate with 
salicylaldehyde 32. An intramolecular oxa-Michael addition of the aldol adduct followed 
by intramolecular acetalization generated 34. Optimization of the reaction conditions 
revealed that the use of sodium carbonate resulted in 35 as the major product, whereas the 
use of triethylamine as base provided 34 as the major product. A variety of 2-
12 
 
hydroxybenzaldehydes were converted either to the tricyclic hemiacetal 34 (10 examples, 
up to 61% yield) or the chromenes 35 (8 examples, up to 81% yield). 
 
 
Scheme 1.11. The base promoted vinylogous aldol reaction of senecialdehyde. 
 
In a related study, Woggon
19
 examined the chiral pyrrolidine mediated vinylogous 
aldol reaction of an aliphatic α,β-unsaturated aldehyde and this methodology was used for 
the synthesis of α-tocopherol. Reaction of aldehyde 36 with phytenal 37 in the presence 
of a diarylprolinol catalyst 38 generated tricyclic hemiacetal 39 through a series of steps 
such as iminium ion formation, vinylogous aldol reaction, intramolecular oxa-Michael 
addition and acetalisation (Scheme 1.12). 
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Scheme 1.12. A vinylogous aldol route to 39. 
 
Recently, Melchiorre
20
 reported the ODVA reaction of α-substituted α,β-
unsaturated aldehydes with isatins (Scheme 1.13). The reaction provided 3-substituted 3-
hydroxyoxindol derivatives 44 with good stereocontrol. Notably, these reactions 
proceeded with very high γ-selectivity.  
 
Scheme 1.13. The ODVA reaction of α-branched enals with isatins. 
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1.2.2 ODVA reaction of cyclic dienes 
In the case of α,β-unsaturated carbonyl compounds such as esters and amides, the 
direct γ-deprotonation with mild organic bases is challenging due to the low acidity of the 
γ-hydrogen atoms. However, the corresponding cyclic derivatives (2(5H)-furanones) are 
readily deprotonated at the γ-position, since this generates the corresponding furanolates. 
As a result, there are several ODVA reactions reported using butenolides as nucleophiles.  
The first example of an ODVA of unsbstituted butenolide was reported by Bhat 
and co-workers.
21
 A few aromatic aldehydes were tested using stoichiometric amounts of 
DABCO to obtain the vinylogous aldol adduct. Subsequently, Zhang et al.
22
 examined 
the vinylogous aldol reaction of dihalofuranones 45 and 46 catalyzed by triethylamine 
(Scheme 1.14). Several aromatic and aliphatic aldehydes were examined and these 
reactions were found to be syn selective. 
 
 
Scheme 1.14. The triethylamine catalyzed ODVA reactions of dihalofuranones. 
 
Terada and co-workers
23
 developed a new class of chiral guanidines 48, with an 
axially chiral binaphthyl backbone, as catalysts for the direct vinylogous aldol (DVA) 
15 
 
reaction. This was the first enantioselective DVA reaction of halogenated furanones 45 
and 46. Various types of aldehydes were examined to afford the major aldol adduct 49b, 
with up to 99% ee (Scheme 1.15). It was also found that dibromofuranone 46 (X = Br) 
provides better diastereo- and enantioselectivity than the corresponding dichlorofuranone. 
 
 
Scheme 1.15. The ODVA reaction catalyzed by chiral guanidine 48. 
 
Recently, Lu et al.
24
 reported the highly diastereo- and enantioselective direct 
vinylogous aldol reactions employing dichlorofuranone 45 and α-ketoesters 50 with the 
tryptophan-derived bifunctional organocatalyst 51 (Scheme 1.16). It was observed that 
aromatic aldehydes exhibit better stereoselection than their aliphatic counterparts. This 
method was also extended to the dibromofuranone 46. 
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Scheme 1.16. The ODVA reaction catalyzed by tryptophan-derived thiourea catalyst. 
 
It should be noted that the Terada guanidine catalysts (Scheme 1.15) are not 
applicable in reactions that employ the parent, unsubstituted γ-crotonolactone 53 as the 
nucleophile precursor, since the decomposition of 53 is significant in these reactions.
23 
In 
addition, the tryptophan-derived catalyst used by Lu also required halofuranones as the 
nucleophile precursors (Scheme 1.16).  
The first examples of ODVA reactions employing the unsubstitited γ-
crotonolactone were reported by Feng and co-workers.
25
 Several aminothiourea catalysts 
derived from diphenylethylenediamine, cyclohexanediamine and cinchona alkaloid based 
diamines were studied. Optimization studies revealed that the quinidine-derived 
aminothiourea 54 was the catalyst of choice when the reactions were carried out in 
diethyl ether at 30 
o
C (Scheme 1.17). Several aromatic aldehydes were used as substrates 
to provide the anti aldol adduct 21a as the major product with a moderate diastereo- (3.8-
5.7:1) and enantioselectivity (78-83% ee). 
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Scheme 1.17. The ODVA reaction catalyzed by thiourea and squaramide. 
 
Simultaneous with the Feng study, the Pansare group
26
 developed similar ODVA 
reactions of γ-crotonolactone with various aromatic aldehydes (Scheme 1.17). Among 
various thiourea and squaramide catalysts, the squaramide catalyst 55 gave the best 
result. Overall, good diastereoselectivities (5-8:1) and excellent enantioselectivities (94- 
>99% ee) were obtained. Chapter 2 of this thesis discusses the details of the development 
of this method. 
Very recently Levacher and Oudeyer
27
 reported an anti selective ODVA reaction 
of (5H)-furan-2-one 56 with aldehydes (Scheme 1.18). The in situ generated chiral 
ammonium amide obtained from the chiral ammonium aryloxide and N,O-
bis(trimethylsilyl)acetamide (BSA) served as the catalyst. In general, the 
diastereoselectivities and enantioselectivities with the aromatic aldehydes (d.r. = 2.3-
18 
 
19:1; 75-92% ee), as well as the aliphatic aldehydes (d.r. = 1.9-9:1; 66-94% ee) were 
good. 
 
Scheme 1.18. The ODVA reaction catalyzed by the combination of chiral quarternary                
                       ammonium aryloxide/N,O-bis(trimethylsilyl)acetamide. 
 
In a recent report,
28
 Melchiorre examined the ODVA reaction of 3-methyl-2-
cyclohexen-1-one with various α-ketoesters (Scheme 1.19). Several aminothiourea 
catalysts derived from diphenylethylenediamine, cyclohexanediamine and cinchona 
alkaloid based diamines were studied. Optimization studies revealed that the 
diphenylethylenediamine-derived aminothiourea 61 was the catalyst of choice. Several 
aromatic as well as aliphatic aldehydes provided the aldol products with good 
enantioselectivity (46-91% ee). It should be noted that these reactions work only with the 
enone 59 as the nucleophile. Attempts to introduce two contiguous stereogenic centers (at 
the λ and δ positions) using differently β-substituted cyclohexenones have been 
19 
 
unsuccessful. Linear enones also proved to be unreactive under the reported reaction 
conditions. 
 
 
Scheme 1.19. The ODVA reaction catalyzed by primary amine thiourea. 
 
1.3 Applications of ODVA reactions 
One of the main focuses in modern organic chemistry is the development of 
efficient synthetic protocols that allow for the straightforward and economical 
construction of natural products with stereogenic complexity. The vinylogous aldol 
reaction uses α,β-unsaturated carbonyl substrates to construct δ-hydroxylated α,β-
unsaturated carbonyls. These functional arrays are common structural motifs in the 
synthesis of enantiomerically pure biologically relevant natural products, especially those 
of polyketide origin.
2a
 This has provided the impetus for developing highly 
stereoselective, catalytic vinylogous aldol reactions. Owing to the growing interest in 
OVMA reactions, much effort has been directed towards their direct application in the 
total synthesis of natural products to demonstrate their utility.
3a
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In nature, vinylogous aldol reactions are used in the construction of complex 
architectures in the forms of alkaloids or diterpenoids. For example, the proposed 
biogenetic pathways to the pentacyclic natural products reserpine 65 and yohimbine 66 
skeletons involve enamine mediated vinylogous aldol reactions. The tetracyclic indole 63 
can undergo an enamine assisted vinylogous aldol reaction leading to intermediate 64, 
which undergoes functional group transformations to yield the products reserpine 65 and 
yohimbine 66 (Scheme 1.20).
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Scheme 1.20. A proposed biogenetic route to reserpine 65 and yohimbine 66. 
 
The organocatalytic, asymmetric vinylogous aldol reaction of 2-furanone is of 
interest because the reaction provides direct access to substituted γ-butenolides, an 
important structural motif in several natural products and biologically active compounds. 
γ-Butenolide derivatives  are potential intermediates for the synthesis of enantiomerically 
pure, functionalized piperidine and tetrahydropyran derivatives. 
21 
 
The ODVA reaction of γ-crotonolactone with aldehydes can be used for the 
synthesis of substance P receptor antagonists (+)-L-733,060 and  (+)-CP-99,994, which 
have been associated with a variety of biological effects including smooth muscle 
contraction, neurogenic inflammation and pain transmission. This methodology is also 
useful for the synthesis of 3-hydroxypipecolic acid, which is a component of tetrazomine, 
an antitumor agent and an antibiotic. The results of this work are described in Chapter 3. 
Chapter 4 will describe a total synthesis of the antimalarial alkaloid (+)-
febrifugine and a formal synthesis of (+)-halofuginone, an antimalarial agent, by 
employing the organocatalytic direct vinylogous aldol reaction.  
This is a publication-based dissertation. As such, each subsequent Chapter is a 
slightly modified version of the publication cited at the beginning of each Chapter. The 
contributions of all authors are explained at the beginning of each Chapter. 
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CHAPTER 2 
 
Organocatalytic Asymmetric Direct Vinylogous Aldol Reactions of 
 γ-Crotonolactone with Aromatic Aldehydes 
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2.1 Introduction  
  The functionalized γ-butenolide (2(5H)-furanone) motif is found in several 
natural products and the synthesis of butenolides has therefore attracted considerable 
interest in recent years.
1
 A popular approach to 5-substituted furanones involves the 
vinylogous Mukaiyama aldol reaction of silyloxyfurans
2
 (Figure 2.1), and a number 
of asymmetric modifications of this reaction are known.
2f-n
 In contrast, the alternative 
approach involving a direct vinylogous aldol reaction of furanones is less explored,
3
 
and asymmetric variants of this reaction employing chiral guanidine, aminothiourea 
and chiral ammonium amide as catalysts are reported.
4
 A detailed account of these 
studies is provided in Chapter 1. 
 
 
Figure 2.1. Direct aldol approach to butenolides. 
 
 
 
  The chiral guanidine-based system
4a
 requires halolactones, and fails when 
crotonolactone is used as the substrate. The aminothiourea mediated reaction requires 
a fourfold excess of the nucleophile
4b
 and there is scope for improvement of the 
stereoselectivity.
4b,c
 Evidently, a catalytic system that addresses these issues would be 
desirable. The following sections describe our findings on the asymmetric, direct 
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vinylogous aldol reaction of crotonolactone with aromatic aldehydes mediated by 
aminothiourea and aminosquaramide catalysts. 
 
2.2 Results and Discussions 
  We initially examined several classes of bifunctional, amine catalysts for the 
direct aldol reaction of crotonolactone: (a) cyclohexanediamine,
5a
 
diphenylethylenediamine,
5b
 cinchonidine
5c,d
 and cinchonine
5e,f
 derived thioureas (1, 2, 
3 and 4), (b) cyclohexanediamine and diphenylethylenediamine derived squaramides 
(5, 6)
5g-i
 and (c) a proline-derived thiourea catalyst (7, Figure 2.2). 
 
Figure 2.2. Bifunctional catalysts examined for the direct vinylogous aldol reaction   
                   of  crotonolactone.  
 
  Orienting experiments were conducted with crotonolactone and benzaldehyde. 
Initially, the aldol reaction was examined with catalysts 1 and 5 in a variety of 
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solvents (Table 2.1).  
 
Entry
a
 Cat
b
 
 
Solvent t/h Yield (%) dr
c
 (anti/syn) ee
d
 (%) (anti) 
1 1 CH2Cl2 84 65 3.0/1 79 
2 1 THF 84 78 5.8/1 76 
3 1 toluene 84 89 1.0/1 78 
4 1 EtOAc 84 72 3.2/1 72 
5 1 CHCl3 84 78 3.0/1 70 
6 1 MeOH 84 81 2.6/1 40 
7 1 DMF 84 63 3.6/1 45 
8 5 CH2Cl2 12 88 2.0/1 49 
9 5 THF 12 89 2.6/1 67 
10 5 CH2Cl2
e
 168 76 5.3/1 94 
11 5 THF
 e
 168 92 5.0/1 90 
12 5 CHCl3
 e
 168 98 5.9/1 91 
13 5 toluene
 e
 168 46 6.7/1 93 
14 5 EtOAc
 e
 168 32 5.6/1 96 
15 5 DMF
 e
 168 65 3.3/1 89 
16 5 CH3CN
 e
 168 35 4.5/1 93 
a 
2 equiv. of crotonolactone. 
b 
20 mol%. 
c  
Determined by 
1
H NMR analysis of crude 
products. 
d 
Chiral HPLC analysis. 
e  
Reaction at 0 
o
C. 
 
Table 2.1. Solvent survey for the vinylogous aldol reaction of crotonolactone. 
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  The reaction proceeded smoothly in most of the solvents examined (Table 
2.1), and the expected aldol product 8a was obtained as a mixture of anti and syn 
diastereomers, with the anti product predominating. Stereochemical assignments are 
based on the reported 
1
H NMR data and the trend in chemical shifts for the syn and 
anti diastereomers of 8.
2c
 Overall, catalyst 1 provided moderate to good 
enantioselectivities for the anti product, except in methanol and DMF (entries 6 and 
7, Table 2.1). Dichloromethane, THF and toluene emerged as promising solvents, 
when catalyst 1 was used, in terms of enantioselectivity, but the complete lack of 
diastereoselectivity in toluene precluded further studies in this solvent (entry 3, Table 
2.1). At room temperature, 5 provided the aldol product 8a with poor enantio- and 
diastereoselectivities in dichloromethane and THF as solvents (entries 8 and 9, Table 
2.1). Much better results were obtained with 5 at 0 
o
C (entries 10-16, Table 2.1). 
Overall, good diastereoselectivities (3.3-6.7:1) and excellent enantioselectivities (89-
96% ee) were obtained in most of the solvents for catalyst 5 at 0 
o
C. Low yields were 
obtained in ethyl acetate (32%) and acetonitrile (35%) (entries 14 and 16, Table 2.1), 
as solvents. From these studies, dichloromethane and THF emerged as promising 
solvents for further investigations. 
  The enantiomeric excess of 8a-l was determined by chiral HPLC comparison 
with racemic samples. The racemic products in this study were prepared by adapting 
the triethylamine catalyzed reaction of dihalofuranones with aldehydes (Scheme 
2.1).
3a
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Scheme 2.1. The triethylamine catalyzed reaction of γ-crotonolactone with aldehydes. 
 
 
 
  Subsequent studies, aimed at identifying the optimal catalyst, were therefore 
conducted in dichloromethane and THF. The results obtained from the catalyst survey 
are summarized in Table 2.2. The diphenylethylenediamine-thiourea catalyst (2) 
provided 8a in relatively low yield and moderate enantioselectivity. In comparison, 
the cinchonidine and cinchonine based catalysts (3 and 4, respectively) generated 8a 
in excellent yields, but the stereoselectivity was low (de: 1.8-4.8/1, ee: 50-71%). 
Much better results were obtained with the squaramide catalyst 5 in dichloromethane 
and THF at 0 
o
C (Table 2.2, entries 9 and 10, 94 and 91% ee). In comparison, the 
diphenylethylenediamine squaramide catalyst 6 was superior to 5 (Table 2.2, entries 
11 and 12, 97 and 96% ee). At ambient temperature, 6 provided 8a in excellent 
enantiomeric excess (97% ee) and good diastereoselectivity (7/1) in dichloromethane. 
Thus, two optimal catalytic systems, providing the anti diastereomer in greater than 
90% ee, were identified from the catalyst and solvent survey, namely (a) the 
cyclohexanediamine squaramide catalyst 5 in dichloromethane at 0 
o
C (entry 9) and 
(b) the diphenylethylenediamine squaramide catalyst 6 in dichloromethane at ambient 
temperature (entry 11, Table 2.2).  
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Entry
a
 Cat
b
 
 
Solvent T/h Yield (%) dr
c
 (anti/syn) ee
d
 (%) (anti) 
1 1 CH2Cl2 84 65 3/1 79 
2 1 THF 84 78 5.8/1 76 
3 2 CH2Cl2 96 32 6.7/1 77 
4 2 THF 84 33 10/1 75 
5 3 CH2Cl2 24 95 3.7/1 64 
6 3 THF 48 95 2/1 50 
7 4 CH2Cl2 24 98 1.8/1 65
e
 
8 4 THF 48 95 4.8/1 71
e
 
9 5 CH2Cl2
f
 168 76 5.3/1 94 
10 5 THF
f
 84 46 4.3/1 91 
11 6 CH2Cl2 120 35 7/1 97 
12 6 THF 120 31 7/1 96 
13 7 CH2Cl2 144 24 3.6/1 14 
14 7 THF 144 25 4.5/1 14 
a 
2 equiv. of crotonolactone. 
b 
20 mol%. 
c  
Determined by 
1
H NMR analysis of crude 
products. 
d 
Chiral HPLC analysis. 
e
 enantiomeric product.  
f  
Reaction at 0 
o
C 
 
Table 2.2. Catalyst survey for the vinylogous aldol reaction of crotonolactone. 
 
  The optimized conditions were employed in a study of the scope of the 
reaction with a variety of aldehydes. These investigations indicated that the choice of 
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catalyst 5 or 6 is determined by the nature of the aldehyde, and high 
enantioselectivities are obtained by proper pairing of the catalyst and aldehyde. 
Nonetheless, for most of the reactions, the diphenylethylenediamine derived catalyst 6 
provided higher enantioselectivities than 5. All isomers of methoxybenzaldehyde 
(entries 3-5, Table 2.3) provide high enantioselectivity. The diastereoselectivity for 
all of the reactions is moderate.
7
 Overall, the level of stereoselection (average dr = 
6/1, average ee = 94%) is higher than that obtained with cinchona alkaloid-thiourea 
catalysts.
4b
 The aldol products 8a-l exhibited spectral data in agreement with 
literature reports.
2,4
 The results of these studies are summarized in Table 2.3. 
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Entry
a
 8 R Cat
b
 Yield (%)
c
 dr
d
 (anti/syn) ee
e
% anti (syn) 
1 b 4-MeC6H4 6 51 8/1 95 (32) 
2 c 4-BrC6H4 6 62 8/1 95 (55) 
3 d 4-MeOC6H4 6 35 8/1 97 (48) 
4 e 2-MeOC6H4 6 58 8/1 96 (84) 
5 f 3-MeOC6H4 6 54 6/1 96 (72) 
6 g 4-ClC6H4 5 50 6/1 94 (83) 
7 h 4-NO2C6H4 6 50 5/1 >99 (50) 
8 i 4-CF3C6H4 6 60 6/1 95 (nd) 
9 j 2-Naphthyl 6 73 6/1 95 (>99) 
10 k Cyclohexyl 5 50 3/1 >99 (>99) 
11 l 1-Naphthyl 6 68 2/1 77 (80) 
a 
2 equiv of crotonolactone;  
b 
20 mol%. 
c 
144 h at 0 
o
C for 5 and 240 h at rt for 6; 
d  1
H 
NMR of crude products. 
e 
Chiral HPLC analysis. 
 
Table 2.3. Vinylogous aldol reaction of crotonolactone with various aldehydes. 
 
 
 
 
  The stereochemical outcome of the reaction is presumably governed by hydrogen 
bonding
8
 of the aldehyde with the squaramide
5g-j
 functionality and an ionic interaction 
of the deprotonated nucleophile and the resultant ammonium group in the catalyst 
(Figure 2.3). We have observed that the triethylamine catalyzed reaction of 
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crotonolactone with aldehydes (used for the preparation of racemic products in this 
study) has an intrinsic preference for the anti diastereomer (dr = ~2/1). The present 
results suggest that the hydrogen bonding functionality in the catalyst enhances this 
diastereoselectivity. 
 
 
Figure 2.3. A proposed transition state assembly for the ODVA reaction leading to the       
        anti aldol product. 
 
2.2.1 Determination of the absolute configuration of 8a 
Hydrogenation (Pd/C) of aldol product 8a in ethyl acetate provided 9 (Scheme 
2.2) which was dextrorotatory ([α]23D = +50.7 (c = 1.0, CHCl3), 88% ee). The positive 
rotation indicates that lactone 9 is enantiomeric to the previously reported
2g
 (5S,1’R) 
isomer ([α]25D = -53.3 (c = 0.22, CHCl3) for 9 with 92% ee). Hydrogenation of 8a in the 
presence of HCl, by adaptation of the literature procedure,
4a
 provided 10 (Scheme 2.2) 
which was assigned the R configuration on the basis of chiral HPLC retention times
7
 
(Chiralcel OD-H, hexanes/2-propanol 80/20, 1 mL/min, 214 nm, tS = 5.95 min, tR = 6.74 
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min). Lactone 9 is therefore assigned the (5R,1’S) configuration, and compounds 8a-l are 
also assigned the (5R,1’S) configuration by analogy. 
 
Scheme 2.2. Hydrogenation and hydrogenolysis of aldol product. 
. 
It was also shown that the aldol products 11a and 11b are diastereomeric at C-1’, 
and not at C-5, by converting the aldol products 11a and 11b into lactam 15a and 15b via 
a series of simple transformations (Scheme 2.3). Hydrogenation of 11 (8/1 mixture of 
11a/11b) to the butyrolactone 12, subsequent mesylation of the secondary alcohol to give 
13 and displacement of the mesylate, with inversion of configuration, by azide anion 
gave the azido butyrolactone 14. Reduction of the azide (H2, Pd/C), in the presence of a 
base (K2CO3), generated the required piperidones 15a and 15b. At this stage, 15a (cis 
isomer) was easily separated from the minor 15b (trans isomer) by flash column 
chromatography. The optical rotation of 15a (cis isomer) was consistent with that 
reported for the (5S,6S) isomer in the literature ([α]D
23
 = +55.3 (c = 1.1, CH2Cl2), 97% ee; 
lit. [α]D
25
 = +52.0 (c = 1.1, CH2Cl2),
8
  for a 99% ee sample). The optical rotation of the 
15b (trans isomer) was opposite to that reported for the (5R,6S) isomer in the literature 
([α]D
23
 = +26.0 (c 1.0 , MeOH), 96% ee; lit. [α]D
20 
= –25.9 (c = 0.27, MeOH),9 for a 92% 
ee sample). Therefore, 15b is assigned the (5S,6R) absolute configuration. These 
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observations indicate that 15b is obtained from the (5S,1’S) isomer of 11b which is 
diastereomeric to 11a at C-1’. The aldol reaction therefore generates aldol products 
which are diastereomeric at the secondary alcohol stereocenter. 
 
 
Scheme 2.3. Conversion of aldol product into lactam. 
 
2.3 Conclusions  
  In conclusion, a highly enantioselective, catalytic aldol reaction of 
crotonolactone with aldehydes was developed. A notable outcome of this study is the 
superior performance of the squaramide catalysts over the conventional 
aminothiourea catalysts.  
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2.4 Experimental section 
General: All commercially available reagents were used without purification. All 
reactions requiring anhydrous conditions were performed under an atmosphere of dry 
nitrogen using oven dried glassware. Dichloromethane and tetrahydrofuran were distilled 
from CaH2 and sodium/benzophenone respectively. Commercial precoated silica gel 
plates were used for TLC. Silica gel for column chromatography was 230-400 mesh. All 
melting points are uncorrected. Optical rotations were measured at the sodium D line on a 
digital polarimeter at ambient temperature. 
 
General Procedure for the organocatalytic direct vinylogous aldol 
reaction: 
 To the catalyst (0.10 mmol, in a 2.0 mL Reacti-Vial
TM
 or a standard 3.0 mL vial) 
was added the aldehyde (0.50 mmol) followed by γ-crotonolactone (2-(5H)-furanone) 
(1.0 mmol) and dichloromethane (0.50 mL). The suspension was stirred for 10 d at room 
temperature (for catalyst 6) or kept for 7 d at 0 
o
C with occassional shaking (for catalyst 
5). The mixture was then diluted with ethyl acetate (1.0 mL) and aqueous HCl (2 N) was 
added. The organic layer was separated and the aqueous layer was extracted with ethyl 
acetate. The combined extracts were dried (Na2SO4) and concentrated. The residue was 
purified by flash chromatography (CH2Cl2/EtOAc, 10/1). The diastereomeric 
composition (anti/syn) was determined by 
1
H NMR analysis of the crude product. The 
enantiomeric excess was determined by HPLC (Chiralpak AD-H or AS-H column, flow 
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rate 1.0 mL/min, UV detection at 210 or 254 nm) by comparison with reported retention 
times
4b
 for compounds 8a-l, and also by comparison with racemic standards (prepared by 
using triethylamine as the catalyst) for compounds 8h, 8i and 8l. The absolute 
configuration of 8a was assigned by correlation. Absolute configurations of 8b-l are 
assigned by analogy within the series. 
 
5-[Hydroxy(phenyl)methyl]furan-2(5H)-one (8a): 
O
O
OH  
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with benzaldehyde (53 µL, 0.50 mmol) 
catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure provided 34 mg 
(35%) of 8a as a white solid.  
IR: 3432, 1728, 1167, 1039, 820 cm
-1
; 
1
H NMR (500MHz, CDCl3): Anti diastereomer: 
δ 7.43-7.34 (m, 6H, ArH and COCH=CH), 6.19 (dd, 1H, J = 5.8, 1.9 Hz, COCH=CH), 
5.19-5.18 (br m, 1H, CH=CHCH), 5.09 (br t, 1H, J = 4.1 Hz, ArCHOH), 2.25 (d, 1H, J = 
3.8 Hz, OH); Syn diastereomer: δ 7.42-7.36 (m, 5H, ArH), 7.17 (dd, 1H, J = 5.8, 1.5 Hz, 
COCH=CH), 6.13 (dd, 1H, J = 5.8, 2.0 Hz, COCH=CH), 5.17 (apparent dt, 1H, J = 7.0, 
1.5 Hz, CH=CHCH), 4.71 (d, 1H, J = 7.0 Hz, ArCHOH), 2.78 (s, 1H, OH); MS (APCI 
pos.): m/z 191.0 (M+1). 
HPLC: Chiralpak AS-H, hexanes/2-propanol 90/10, 254 nm, t1 = 27.8 min (major anti), t2 
= 36.2 min, (syn), t3 = 49.6 min (syn), t4 = 66.8 min (minor anti). Ee: 97% (anti). 
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5-[Hydroxy(p-tolyl)methyl]furan-2(5H)-one (8b): 
O
O
OH
CH3
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 4-methylbenzaldehyde (59 µL, 0.50 
mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure provided 
52 mg (51%) of 8b as a white solid.  
IR: 3401, 1736, 1325, 1170, 1102, 1079, 1039, 917, 877 cm
-1
; 
1
H NMR (500MHz, 
CDCl3): Anti diastereomer: δ 7.36 (dd, 1H, J = 5.8, 1.4 Hz, COCH=CH), 7.28 (d, 2H, J 
= 8.0 Hz, ArH), 7.22 (d, 2H, J = 8.0 Hz, ArH, ortho to CH3), 6.18 (dd, 1 H, J = 5.8, 2.0 
Hz, COCH=CH), 5.17-5.15 (m, 1H, CH=CHCH), 5.04 (br t, 1H, J = 4.0 Hz, ArCHOH), 
2.37 (3H, CH3), 2.22 (d, 1H, J = 4.0 Hz, OH), 2.37 (3H, CH3); Syn diastereomer: δ 7.28 
(d, 2H, J= 8.0 Hz, ArH), 7.22 (d, 2H, J = 8.0 Hz, ortho to CH3), 7.16 (dd, 1H, J = 5.8, 1.6 
Hz, COCH=CH), 6.13 (dd, 1H, J = 5.8, 2.0 Hz, COCH=CH), 5.15-5.17 (m, 1H, 
CH=CHCH), 4.66 (dd, 1H, J = 6.9, 3.0 Hz, ArCHOH), 2.58 (d, 1H, J = 3.0 Hz, OH), 
2.37 (3H, CH3); MS (APCI pos.): m/z 205.0 (M+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 95/5, 254 nm, t1 = 20.0 min (major anti), t2 
= 22.2 min, (minor anti), t3 = 26.8 min (minor syn), t4 = 29.0 min (major syn). Ee: 95% 
(anti). 
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5-[Hydroxy(4-bromophenyl)methyl]furan-2(5H)-one (8c): 
O
O
OH
Br
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 4-bromobenzaldehyde (93 mg, 0.50 
mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure provided 
83 mg (62%) of 8c as a white solid.  
IR: 3343, 1742, 1486, 1399, 1191, 1176, 1095, 1074, 1041, 1008, 917, 880, 831, 808   
cm
-1
; 
1
H NMR (500MHz, CDCl3): Anti diastereomer: δ 7.55 (d, 2H, J = 8.4 Hz, ArH, 
ortho to Br), 7.32 (dd, 1H, J = 5.8, 1.4 Hz, COCH=CH), 7.29 (d, 2H, J = 8.5 Hz, ArH), 
6.19 (dd, 1 H, J = 5.8, 2.0 Hz, COCH=CH), 5.15-5.13 (m, 1H, CH=CHCH), 5.04 (t, 1H, 
J = 4.0 Hz, ArCHOH), 2.48 (d, 1H, J = 4.0 Hz, OH); Syn diastereomer: δ 7.55 (d, 2H, J 
= 8.4 Hz, ArH, ortho to Br), 7.29 (d, 2H, J = 8.4 Hz), 7.20 (dd, 1H, J = 5.8, 1.5 Hz, 
COCH=CH), 6.14 (dd, 1H, J = 5.8, 2.0 Hz, COCH=CH), 5.15-5.13 (m, 1H, CH=CHCH), 
4.73 (dd, 1H, J = 6.7, 3.3 Hz, ArCHOH), 2.73 (d, 1H, J = 3.3 Hz, OH); MS (APCI pos.): 
m/z 269.1 (M
+
). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 88/12, 254 nm, t1 = 9.6 min (major anti), t2 
= 10.4 min (minor syn), t3 = 10.8 min (minor anti), t4 = 11.6 min (major syn). Ee: 95% 
(anti). 
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5-[Hydroxy(4-methoxyphenyl)methyl]furan-2(5H)-one (8d): 
O
O
OH
OCH3
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 4-methoxybenzaldehyde (63 µL, 
0.50 mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure 
provided 39 mg (35%) of 8d as a white solid.  
IR: 3357, 1742, 1585, 1510, 1242, 1171, 1101, 1085, 1029, 1008, 877, 827, 814 cm
-1
; 
1
H 
NMR (500MHz, CDCl3): Anti diastereomer: δ 7.39 (dd, 1H, J = 5.8, 1.5 Hz, 
COCH=CH), 7.32 (d, 2H, J = 8.7 Hz, ArH), 6.93 (d, 2H, J = 8.7 Hz, ortho to OCH3),  
6.18 (dd, 1 H, J = 5.8, 2.0 Hz, COCH=CH), 5.15-5.14 (m, 1H, CH=CHCH), 5.0 (t, 1H, J 
= 4.0 Hz, ArCHOH), 3.82 (s, 3H, OCH3), 2.26 (d, 1H, J = 4.0 Hz, OH); Syn 
diastereomer: δ 7.32 (d, 2H, J = 8.7 Hz, ArH), 7.16 (dd, 1H, J = 5.8, 1.6 Hz, 
COCH=CH), 6.93 (d, 2H, J = 8.7 Hz, ortho to OCH3),  6.13 (dd, 1H, J = 5.8, 2.1 Hz, 
COCH=CH), 5.15-5.14 ( m, 1H, CH=CHCH), 4.65 (dd, 1H, J = 7.1, 3.0 Hz, ArCHOH), 
3.82 (s, 3H, OCH3), 2.61 (d, 1H, J = 3.0 Hz, OH); MS (APCI pos.): m/z 221.0 (M+1), 
203.0 ((M-H2O)+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 90/10, 254 nm, t1 = 15.1 min (major anti), 
t2 = 17.7 min, (minor anti), t3 = 19.0 min (minor syn), t4 = 20.7 min (major syn). Ee: 97% 
(anti). 
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5-[Hydroxy(2-methoxyphenyl)methyl]furan-2(5H)-one (8e): 
O
O
OH OCH3  
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 2-methoxybenzaldehyde (63 µL, 
0.50 mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure 
provided 64 mg (58%) of 8e as a colorless liquid.  
IR: 3418, 1733, 1601, 1491, 1462, 1238, 1160, 1095, 1036, 1022, 816 cm
-1
; 
1
H NMR 
(500MHz, CDCl3): Anti diastereomer: δ 7.40 (dd, 1H, J = 5.8, 1.0, COCH=CH), 7.34-
7.31 (m, 2H, ArH ortho and para to OCH3), 7.03 (t, 1 H, J = 7.5 Hz, ArH, meta to OCH3), 
6.92 (d, 1H, J = 8.3, ArH), 6.15 (dd, 1 H, J = 5.8, 2.0 Hz, COCH=CH), 5.38-5.37 (m, 1H, 
CH=CHCH), 5.31 (t, 1H, J = 5.7 Hz, ArCHOH), 3.89 (s, 3H, OCH3), 2.82 (d, 1H, J = 5.7 
Hz, OH); Syn diastereomer: δ  7.34-7.31 (m, 2H,  ArH ortho and para to OCH3), 7.18 
(dd, 1H, J = 5.8, 1.1, COCH=CH),  7.03 (t, 1 H, J = 7.5 Hz, ArH, meta to OCH3), 6.92 (d, 
1H, J = 8.3, ArH ), 6.12 (dd, 1H, J = 5.8, 2.0 Hz, COCH=CH), 5.24-5.23 (br dt, 1H, J = 
6.6, 1.5, CH=CHCH)  5.02 (t, 1H, J = 5.7 Hz, ArCHOH), 3.85 (s, 3H, OCH3), 3.06 (d, 
1H, J = 5.7 Hz, OH); MS (APCI neg.): m/z 219 (M
+
); APCI pos. m/z 203.0 ((M-H2O)+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 85/15, 254, t1 = 8.4 min (major anti), t2 = 
11.0 min, (minor anti), t3 = 12.9 min (major syn), t4 = 16.3 min (minor syn). Ee: 96% 
(anti). 
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5-[Hydroxy(3-methoxyphenyl)methyl]furan-2(5H)-one (8f): 
O
O
OH
OCH3
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 3-methoxybenzaldehyde (63 µL, 
0.50 mmol) catalyzed by 6 (55 mg, 0. 10 mmol) according to the general procedure 
provided 60 mg (54%) of 8f as a colorless liquid.  
IR: 3420, 1735,1600, 1585, 1489, 1456, 1435, 1256, 1157, 1034, 825 cm
-1
; 
1
H NMR 
(500MHz, CDCl3): Anti diastereomer: δ 7.35-7.29 (m, 2H, ArH, COCH=CH), 6.97-6.87 
(m, 3H,  ArH),  6.17 (dd, 1 H, J = 5.8, 2.0 Hz, COCH=CH), 5.18-5.15 (m, 1H, 
CH=CHCH), 5.08 (t, 1H, J = 4.0 Hz, ArCHOH), 3.82 (s, 3H, OCH3), 2.73(d, 1H, J = 4.0 
Hz, OH); Syn diastereomer: δ 7.35-7.29 (m, 1H, ArH), 7.18 (dd, 1H, J = 5.8, 1.4 Hz, 
COCH=CH), 6.97-6.87 (m, 3H, ArH), 6.12 (dd, 1H, J = 5.8,1.9 Hz, COCH=CH), 5.18-
5.15 (m, 1H, CH=CHCH), 4.68 (dd, 1H, J = 7.0, 3.1 Hz, ArCHOH), 3.82 (s, 3H, OCH3), 
2.94 (d, 1H, J = 3.1 Hz, OH); MS (APCI pos.): m/z 221.0 (M+1), 203.0 ((M-H2O)+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 90/10, 210 nm, t1 = 14.2 min (major anti), 
t2 = 18.3 min, (minor anti),  t3 = 20.0 min (minor syn), t4 = 21.4 min (major syn). Ee: 96% 
(anti). 
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5-[Hydroxy(4-chlorophenyl)methyl]furan-2(5H)-one (8g): 
O
O
OH
Cl
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 4-chlorobenzaldehyde (70 mg, 0.50 
mmol) catalyzed by 5 (45 mg, 0.10 mmol) according to the general procedure provided 
56 mg (50%) of 8g as a white solid.  
IR: 3420, 1732, 1491, 1175, 1093, 1078, 1042, 917, 852, 812 cm
-1
; 
1
H NMR (500MHz, 
CDCl3): Anti diastereomer: δ 7.40-7.31 (m, 5H, ArH, COCH=CH),  6.20 (dd, 1 H, J = 
5.8, 2.0 Hz, COCH=CH), 5.15-5.13 (m, 1H, CH=CHCH), 5.05 (t, 1H, J = 4.0 Hz, 
ArCHOH), 2.38 (d, 1H, J = 4.0 Hz, OH); Syn diastereomer: δ 7.40-7.31 (m, 4H, ArH),  
7.20 (dd, 1H, J = 5.8, 1.5 Hz, COCH=CH), 6.14 (dd, 1H, J = 5.8,2.0 Hz, COCH=CH), 
5.15-5.13 (m, 1H, CH=CHCH), 4.74 (dd, 1H, J = 6.8, 3.2 Hz, ArCHOH), 2.67 (d, 1H, J = 
3.2 Hz, OH); MS (APCI pos.): m/z 225.0 (M+1), 207.0 ((M-H2O)+1). 
HPLC: Chiralpak AD-H hexanes/2-propanol 95/5, 210 nm, t1 = 21.1 min (major anti), t2 
= 24.2 min, (minor anti), t3 = 25.9 min (major syn), t4 = 29.4 min (minor syn). Ee: 94% 
(anti). 
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5-[Hydroxy(4-nitrophenyl)methyl]furan-2(5H)-one (8h): 
O
O
OH
NO2
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 4-nitrobenzaldehyde (76 mg, 0.50 
mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure provided 
59 mg (50%) of 8h as a yellow solid.  
IR: 3438, 1746, 1515, 1348, 1169, 1103, 1039, 916, 833 cm
-1
; 
1
H NMR (500MHz, 
CDCl3): Anti diastereomer: δ 8.26 (d, 2H, J = 8.7 Hz, ArH, ortho to NO2 ), 7.63 (d, J = 
8.7, 2H, ArH), 7.30 (dd, 1H, J = 5.9,1.6 Hz, COCH=CH),  6.17 (dd, 1 H, J = 5.9, 1.8 Hz, 
COCH=CH), 5.21-5.19 ( m, 2H, CH=CHCH, ArCHOH),  2.77 (d, 1H, J = 3.7 Hz, OH); 
Syn diastereomer: δ 8.29 (d, 2H, J = 8.7 Hz, ArH, ortho to NO2 ), 7.66-7.59 (m, 2H, 
ArH), 7.21 (m, 1H, COCH=CH),  6.24 (dd, 1 H, J = 5.8, 1.4 Hz, COCH=CH), 5.0-4.98 
(m, 2H, CH=CHCH, ArCHOH), 2.59 (d, 1H, J = 3.5 Hz, OH); MS (APCI pos.): m/z 
236.1 (M+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 95/5, 254 nm, t1 = 52.4 min (major anti), t2 
= 59.1 min, (major syn), 70.5 (minor syn). Ee: >99% (anti). 
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5-[Hydroxy(4-trifluoromethylphenyl)methyl]furan-2(5H)-one (8i): 
O
O
OH
CF3
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 4-trifluoromethylbenzaldehyde (67 
µL, 0.50 mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure 
provided 78 mg (60%) of 8i as a colorless solid.  
IR: 3413, 1739, 1322, 1161, 1100, 1065, 1040, 1016, 816 cm
-1
; 
1
H NMR (500MHz, 
CDCl3): Anti diastereomer: δ 7.68 (d, 2H, J = 8.1  ArH), 7.55 (d, 2H, J = 8.1, ArH), 
7.31 (dd, 1H, J = 5.8, 1.4 Hz, COCH=CH),  6.21 (dd, 1 H, J = 5.8, 2.0 Hz, COCH=CH), 
5.19-5.14 (m, 2H, CH=CHCHO, ArCHOH), 2.38 (d, 1H, J = 3.9 Hz, OH); Syn 
diastereomer: δ 7.68 (d, 2H, J = 5.7, ArH), 7.55 (d, 2H, J = 5.7, ArH), 7.24 (dd, 1H, J = 
5.8, 1.5 Hz, COCH=CH),  6.15 (dd, 1 H, J = 5.8, 2.0 Hz, COCH=CH), 5.19-5.14 (m, 1H, 
CH=CHCH), 4.91  (m, 1H, ArCHOH), 2.38 (d, 1H, J = 3.4 Hz, OH); MS (APCI pos.): 
m/z 259.2 (M+1), 241.1 ((M-H2O)+1).  
HPLC: Chiralpak AD-H, hexanes/2-propanol 97/3, 254 nm, t1 = 28.9 min (major anti), t2 
= 32.4 min, (minor anti). Ee: 95% (anti). 
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5-[Hydroxy (naphthalen-2-yl)methyl]furan-2(5H)-one (8j): 
O
O
OH  
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 2-naphthaldehyde (78 mg, 0.50 
mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure provided 
88 mg (73%) of 8j as a pale yellow solid.  
IR: 3359, 1752, 1731, 1172, 1077, 1041, 824 cm
-1
; 
1
H NMR (500MHz, CDCl3): Anti 
diastereomer: δ 7.90-7.85 (m, 4H, ArH), 7.53-7.50 (m, 3H, ArH), 7.36 (dd, 1H, J = 5.8, 
1.4 Hz COCH=CH), 6.19 (dd, 1 H, J = 5.8, 1.9 Hz, COCH=CH), 5.29-5.26 ( m, 2H, 
CH=CHCH, ArCHOH), 2.51 (d, 1H, J = 3.7 Hz, OH); Syn diastereomer: δ 7.90-7.85 
(m, 4H, ArH), 7.53-7.50 (m, 3H, ArH), 7.18 (dd, 1H, J = 5.8, 1.6 Hz, COCH=CH), 6.13 
(dd, 1H, J = 5.8, 2.0 Hz, COCH=CH), 5.29-5.26 (m, 2H, CH=CHCH), 4.88 (dd, 1H, J = 
7.1, 3.1 Hz, ArCHOH), 2.81 (d, 1H, J = 3.1 Hz, OH); MS (APCI pos.): m/z 241.0 (M+1), 
223.0 ((M-H2O)+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 85/15, 254 nm, t1 = 9.5 min (major anti), t2 
= 11.8 min, (minor anti), t3 = 12.6 min (major syn), t4= 13.6 min (minor syn). Ee: 95% 
(anti). 
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 5-[Hydroxy(cyclohexyl)methyl]furan-2(5H)-one (8k): 
O
O
OH  
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with cyclohexanecarboxaldehyde (60 
µL, 0.50 mmol) catalyzed by 5 (45 mg, 0.10 mmol) according to the general procedure 
provided 49 mg (50%) of 8k as a white solid.  
IR: 3420, 1747,  1715, 1154, 1112, 1096, 1029, 1004, 870, 845 829 cm
-1
; 
1
H NMR 
(500MHz, CDCl3): Anti diastereomer: δ 7.59 (dd, 1H, J = 5.8, 1.4 Hz, COCH=CH), 
6.19 (dd, 1 H, J = 5.8, 1.9 Hz, COCH=CH), 5.10 (dt, 1H, J = 5.7, 1.6 Hz, CH=CHCH), 
3.61 (apparent q, 1H, J = 5.6 Hz, ArCHOH), 1.98-1.96 (m, 1H, CHCH2), 1.82-1.54 (m, 
4H, CH2), 1.33-1.10 (m, 6H, CH2); Syn diastereomer: δ 7.45 (dd, 1H, J = 5.8, 1.5 Hz, 
COCH=CH),  6.19 (dd, 1H, J = 5.8, 1.9 Hz, COCH=CH), 5.18 (m, 1H, CH=CHCH), 
3.49-3.45 (m, 1H, ArCHOH), 1.98-1.96 (m, 1H, CHCH2), 1.82-1.54 (m, 4H, CH2), 1.33-
1.10 (m, 6H, CH2); MS (APCI pos.): m/z 197.0 (M+1), 179.1 ((M-H2O)+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 95/5, 210 nm, t1= 15.4 min (major anti), t2 
= 17.5 min (major syn). Ee: >99% (anti). 
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5-[Hydroxy(naphthalen-1-yl)methyl]furan-2(5H)-one (8l): 
 
Reaction of γ-crotonolactone (70 µL, 1.0 mmol) with 1-naphthaldehyde (68 µL, 0.50 
mmol) catalyzed by 6 (55 mg, 0.10 mmol) according to the general procedure provided 
82 mg (68%) of 8k as a yellow solid.  
IR: 3414, 1730,  1165, 1102, 1081, 1042, 882, 823, 797, 775  cm
-1
; 
1
H NMR (500MHz, 
CDCl3): Anti diastereomer: δ 8.02 (d, 1H, J = 8.5 Hz, ArH), 7.93 (d, 1H, J = 7.6 Hz, 
ArH), 7.88 (d, 1H, J = 8.0 Hz, ArH), 7.74 (d, 1H, J = 7.2 Hz, ArH), 7.59-7.53 (m, 3H, 
ArH & COCH=CH), 7.27-7.25 (m, 1H, ArH), 6.20 (dd, 1 H, J = 5.8, 2.0 Hz, 
COCH=CH), 5.98 ( t, 1H, J = 3.5 Hz, CH=CHCH), 5.44-5.43 (m, 1H, ArCHOH), 2.57 
(d, 1H, J = 3.8 Hz, OH); Syn diastereomer: δ 7.98 (m, 1H, ArH), 7.88-7.87 (m, 2H, 
ArH), 7.74 (d, 1H, J = 7.0 Hz, ArH), 7.59-7.53 (m, 3H, ArH & COCH=CH), 7.27-7.25 
(m, 1H, ArH), 6.95 (dd, 1H, J = 5.8, 1.5 Hz, COCH=CH), 6.14 (dd, 1H, J = 5.8, 2.0 Hz, 
COCH=CH), 5.46-5.45 (m, 1H, CH=CHCH), 5.39 (dt, 1H, J = 3.4, 1.6 Hz, ArCHOH), 
2.92 (d, 1H, J = 3.2 Hz, OH); MS (APCI pos.): m/z 241.0 (M+1), 223.0 ((M-H2O)+1). 
HPLC: Chiralpak AD-H, hexanes/2-propanol 85/15, 254 nm, t1= 8.7 min (major anti), t2 
= 9.5 min (minor anti), t3 = 13.8 min (major syn), t4= 17.3 min (minor syn). Ee: 77% 
(anti). 
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2.6 Selected 
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H NMR spectra 
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2.7 Selected HPLC chromatograms 
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CHAPTER 3 
 
Synthesis of (+)-L-733,060, (+)-CP-99,994 and  
(2S,3R)-3-Hydroxypipecolic Acid: Application of an Organocatalytic 
Direct Vinylogous Aldol Reaction 
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3.1 Introduction  
The piperidine motif is found in numerous biologically relevant natural products
1
 
as well as in medicinal and pharmaceutical agents,
2
 and the synthesis of functionalized 
piperidines has therefore continued to engage synthetic chemists over the years.
3
 
Stereoselective routes to aryl substituted
4
 and hydroxylated piperidines
5
 have been 
extensively investigated. In particular, the biological activity and the synthesis of a 
variety of 2,3-disubstituted piperdines has attracted considerable interest. This is perhaps 
best exemplified by the synthetic efforts directed towards the neurokinin receptor 
antagonists (+)-L-733,060
6
 and (+)-CP-99,994;
7
 as well as (2S,3R)-3-hydroxypipecolic 
acid,
8
 a constituent of the antibiotic tetrazomine (Figure 3.1). The following sections 
describe organocatalysis based enantioselective syntheses of these three targets.  
 
 
Figure 3.1. Biologically active 2,3-disubstituted piperidines targeted in this study.  
 
3.2 Known synthetic routes to (+)-L-733,060, (+)-CP-99,994 and (2S,3R)-
3-hydroxypipecolic acid 
           The following summary provides an overview of the reported syntheses of  
(+)-L-733,060, (+)-CP-99,994 and (2S,3R)-3-hydroxypipecolic acid from 2010 onwards. 
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3.2.1 Synthesis of (+)-L-733,060 
In 2010, Garrido and coworkers reported
6a
 an enantioselective synthesis of (+)-L-
733,060. The synthesis starts with the Baylis-Hillman reaction of methylacrylate 1 and 
benzaldehyde 2 (Scheme 3.1). The Baylis-Hillman adduct 3 obtained was treated with 
acetic anhydride and pyridine to give 4. A domino reaction (stereoselective Ireland-
Claisen rearrangement of the enolate derived from 4 followed by a Michael addition of 5 
to the resulting compound) of 4 and chiral lithium amide 5 afforded optically pure γ-
substituted δ-aminoacid 6. Hydrogenolysis of 6 using Pd/C in AcOH and subsequent in 
situ lactamization gave 7. The methyl ketone 9 was obtained by converting the piperidin-
2-one 7 into Weinreb amide 8 followed by addition of methylmagnesium bromide. 
Baeyer-Villiger oxidation of 9 with urea hydrogen peroxide (UHP) provided lactam 10. 
The lactam 10 was reduced using LiAlH4 and subsequent treatment with (Boc)2O, 
afforded the N-Boc amino alcohol 11. The inversion of hydroxyl group is necessary for 
the synthesis of (+)-L-733,060. Oxidation of 11 with NMO/TPAP followed by 
stereoselective reduction using CeCl3 and NaBH4, gave the desired piperidine 13. O-
Alkylation of 13 with 3,5-bis(trifluoromethyl)benzyl bromide followed by deprotection 
provided (+)-L-733,060 (12 steps from Baylis-Hillman adduct 3, 5.6% overall yield). 
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                 Scheme 3.1. Synthesis of (+)-L-733,060 by Garrido. 
 
In the same year, Haddad and coworkers reported
6b
 the synthesis of (+)-L-
733,060 (Scheme 3.2). The synthesis began with the addition of phenyllithium to ethyl 
glycidate 14 to provide epoxyketone 15. Reductive amination of 15 gave the 
corresponding anti aminoepoxide 16 as a single diastereomer after flash chromatography. 
The aminoepoxide was treated with di-tert-butyldicarbonate to provide the oxazolidinone 
17 through regioselective intramolecular epoxide opening. The oxazolidinone 17 was 
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treated with NaOH/EtOH followed by a selective protection of the primary alcohol as 
tert-butyldimethylsilyl ether to provide the amino alcohol 18. Hydrogenolysis of 18 with 
Pd/C in the presence of di-tert-butyldicarbonate afforded 19. Oxazolidine 20 was 
obtained by the treatment of 19 with 2,2-dimethoxypropane followed by the deprotection 
of primary alcohol. Oxidation of 20 using Dess-Martin periodinane (DMP) gave the 
corresponding aldehyde, which was then subjected to a Horner-Wadsworth-Emmons 
reaction to provide the ester 21. Unmasking of the 1,2-amino alcohol moiety in 21 
followed by hydrogenation provided the saturated ester, which underwent in situ 
cyclization to form the piperidinone 22. Reduction of 22 using LiAlH4 followed by 
treatment with (Boc)2O, provided the N-Boc aminoalcohol 13. O-Alkylation of 13 with 
3,5-bis(trifluoromethyl)benzyl bromide followed by deprotection provided (+)-L-733,060 
(16 steps from ethyl glycidate 14, 5.3% overall yield). 
 73 
 
 
                 Scheme 3.2. Synthesis of (+)-L-733,060 by Haddad. 
 
3.2.2 Synthesis of (+)-CP-99,994 
Garrido and coworkers reported
6a
 an enantioselective synthesis of (+)-CP-99,994 
(Scheme 3.3). The ketone 12 undergoes reductive amination followed by deprotection 
provided (+)-CP-99,994. The synthesis of ketone 12 is described in Scheme 3.1. 
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                                    Scheme 3.3. Synthesis of (+)-CP-99,994 by Garrido. 
 
In 2012, Bhat and coworkers reported
7d
 an enantioselective synthesis of (+)-CP-
99,994 (Scheme 3.4). The synthesis began with enantiomerically pure L-ornithine 24, 
which was protected with benzyl chloroformate to afford 25 in excellent yield. 
Compound 25 was converted to N-methoxy-N-methylamide 26 which was treated with 
phenylmagnesium bromide at -78 
o
C in THF to provide ketone 27. The 
diaminophenylketone 27 was treated with trimethylsilyl triflate and triethylsilane at -78 
o
C to afford the piperidine derivative 28 with good diastereoselectivity (24/1) resulting 
from cyclization of 27 via an N-acyliminium ion. Deprotection of 28 followed by 
reductive N-alkylation of the primary amine with 2-methoxybenzaldehyde provided CP-
99,994 (7 steps from L-ornithine 24, 40% overall yield). 
. 
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Scheme 3.4. Synthesis of (+)-CP-99,994 by Bhat. 
 
3.2.3. Synthesis of (2S,3R)-3-hydroxypipecolic acid 
In 2010, Lee and coworkers reported
8b
 a synthesis of (2S,3R)-3-hydroxypipecolic 
acid. The synthesis started from monoprotected amino alcohol 29 (Scheme 3.5), which 
was obtained from butane-1,4-diol in three steps. The amino alcohol 29 was added to 
optically active acetylenic sulfoxide 30 under basic conditions (Et3N, DMAP) to afford 
sulfonamide 31 as a 5/1 Z:E mixture. After separation, Z-31 was oxidized to aldehyde 32 
with 2-iodoxybenzoic acid (IBX). A highly diastereoselective radical cyclization took 
place, when aldehyde 32 was treated with SmI2 in methanol and the only product formed 
was the 3-hydroxypiperidine 33 (dr = 100:0, 72%). After protection of the alcohol as a 
tert-butyldimethylsilyl ether (TBSCl, imidazole, DMAP), a Pummerer rearrangement 
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was performed and reduction of the Pummerer product gave the primary alcohol 34. The 
hydroxypiperidine 34 was oxidized in two steps (DMP, followed by NaClO2) to the 
corresponding carboxylic acid. After a deprotection with cesium fluoride, (2S,3R)-3-
hydroxypipecolic acid was obtained (8 steps from 29, 19% overall yield). 
 
 
Scheme 3.5. Synthesis of (2S,3R)-3-hydroxypipecolic acid by Lee. 
 
A strategy involving ring-closing metathesis (RCM) to build the piperidine core 
of 3-hydroxypipecolic acid by C–C bond formation was reported recently by 
Chattopadhyay.
8f
 Serinol derivative 35 was protected as a benzyl ether followed by the 
oxazolidine ring opening under acidic conditions to provide 36 (Scheme 3.6). Swern 
oxidation of 36 provided the corresponding aldehyde. Treatment of the aldehyde with 
vinylmagnesium bromide afforded syn-allylic alcohol 37 as the major isomer (dr = 6.7:1). 
Unfortunately, the syn isomer could not be separated from the minor anti isomer 38. 
After conversion of the mixture of 37 and 38 into their MOM ether derivatives and N-
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allylation (NaH, allyl bromide), the pure syn isomer 39 was separated by column 
chromatography. Ring-closing metathesis (RCM) of 39 with the first-generation Grubbs 
catalyst 40 gave the desired dehydropiperidine derivative 41. Hydrogenation of 41 
afforded the piperidine derivative 42, which was subjected to a two-step oxidation (DMP 
and Pinnick oxidation) to furnish the carboxylic acid. Deprotection of the Boc and MOM 
groups under acidic conditions provided the desired (2S,3R)-3-hydroxypipecolic acid (11 
steps from 35, 10.5% overall yield). 
 
 
Scheme 3.6. Synthesis of (2S,3R)-3-hydroxypipecolic acid by Chattopadhyay. 
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3.3 Results and Discussions 
The 2-substituted 3-hydroxy piperidine motif A is accessible by the 
rearrangement of 5-(1-aminoalkyl or -aminoaryl) butyrolactones B (Figure 3.2).
9
 The 
aminobutyrolactones can, in turn, be obtained from the corresponding hydroxy precursors 
C, which are typically obtained by stereoselective vinylogous Mukaiyama aldol reactions 
of 2-siloxyfurans and aldehydes
.10
 However, a much simpler route to stereodefined 5-(1-
hydroxyalkyl/aryl) butenolides involves the organocatalytic, direct vinylogous aldol 
reaction of -crotonolactone (2(5H)-furanone) with aldehydes, a reaction that has 
received attention only recently.
11
 Given the structural similarities in the targets of the 
present study (Figure 3.1), it appeared that a suitably functionalized butyrolactone could 
potentially be employed as a common synthetic precursor to achieve most of the 
objectives. In addition, this synthetic strategy would also highlight the utility of the 
organocatalytic direct vinylogous aldol (ODVA) reaction (Figure 3.2). 
 
 
Figure 3.2. The organocatalytic direct vinylogous aldol route to functionalized  
                            piperidines. 
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 Our studies therefore began with the synthesis of 45 (Scheme 3.7) and its 
conversion to (5S,6S)-5-hydroxy-6-phenylpiperidin-2-one (22) which is an advanced 
precursor to (+)-L-733,060 and (+)-CP-99,994. Initially, the direct vinylogous aldol 
reaction of commercially available γ-crotonolactone and benzaldehyde was examined in 
the presence of selected aminothiourea and aminosquaramide catalysts derived from 
diphenylethylenediamine, 1,2-cyclohexane diamine and amines obtained from cinchona 
alkaloids. The details of these studies were described in Chapter 2 (pages 27-32). 
Extensive optimization studies with these catalysts revealed the aminosquaramide 44
12
 as 
the most efficient catalyst in terms of the yield, diastereoselectivity and enantioselectivity 
for the aldol product.
11c
 Thus, the direct vinylogous aldol reaction of γ-crotonolactone 
with benzaldehyde provided the butenolide 45 in good yield and diastereoselectivity 
(74%, anti/syn = 8/1) and excellent enantiomeric excess (>99% ee for the anti 
diastereomer) when the reaction was conducted in dichloromethane at ambient 
temperature (Scheme 3.7). 
 
Scheme 3.7. Conversion of aldol product to lactam employing ODVA reaction. 
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The aldol product 45 (as a diastereomeric mixture) was easily converted to the 
lactam 22 via a series of simple transformations. Hydrogenation of 45 to the 
butyrolactone 46, subsequent mesylation of the secondary alcohol to give 47 and 
displacement of the mesylate, with inversion of configuration, by azide anion gave the 
azido butyrolactone 48. It should be mentioned that the attempted mesylation of 45 
exclusively resulted in its dehydration (Scheme 3.8).  
 
 
Scheme 3.8. Dehydration of aldol product. 
 
The unwanted dehydration side reaction is effectively prevented by prior 
reduction of the double bond in 44. Reduction of the azide (H2, Pd/C) generated a 
mixture of the corresponding amino butyrolactone and the required piperidone 22 
resulting from an intramolecular N-acylation of the amino lactone. Notably, 
hydrogenation of the azide in the presence of a base (K2CO3) significantly facilitated this 
rearrangement to directly provide 22 without any residual amino lactone. At this stage, 
cis-22 was easily separated from the minor (trans) diastereomer by flash chromatography 
and all further transformations were carried out with diastereomerically pure cis-22. The 
overall conversion of 44 to 22 is quite efficient (76% yield over four steps) and can be 
conducted without purification of any of the intermediates.  
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Scheme 3.9. Synthesis of (+)-L-733,060. 
 
Reduction of the piperidinone 22 with borane
6e
 provided the corresponding 
piperidine (50, 96%) (Scheme 3.9), which was converted to the N-Boc derivative 13. The 
conversion of 13 to the neurokinin receptor antagonist targets was achieved by adaptation 
and some modification of previously described methods (Scheme 3.9). O-Alkylation of 
13 with 3,5-bis(trifluoromethyl)benzylbromide followed by deprotection provided (+)-L-
733,060 (9 steps from benzaldehyde, 24.8% overall yield).  
The synthesis of (+)-CP-99,994 required the synthesis of ketone 12 and 
subsequent reductive amination (Scheme 3.11), and both of these steps required detailed 
attention to the reaction conditions. Oxidation of 13 with Dess-Martin periodinane 
provided the 3-piperidinone 12 (77%, 94% ee). Notably, in our hands, the enantiomeric 
excess of 12 was dependent on the method of oxidation and the DMP procedure
13
 is by 
far the best for obtaining 12 in good yield and high enantiomeric excess. Oxidation of 13 
with IBX or IBX/DMSO with heating led to 12 with diminished ee as compared to 13. 
Swern oxidation of 13 is reported to provide 12 without racemization.
14
 In the present 
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study, Swern oxidation of 13 (96% ee) provided 12 with 76% ee. Oximation of 12 
obtained in situ from the Swern oxidation of 13 (ee of 13 = 93%), eventually provided 
CP-99,994 with 60% ee. Similarly, the reaction of 12 (87% ee) with methoxylamine 
hydrochloride in pyridine as the solvent
13
 subsequently provided CP-99,994 with 50% ee. 
Changing the solvent to ethanol and employing only the necessary amount of pyridine 
was found to be important for minimizing the racemization of 12. Likewise, direct 
imination of 12 with the appropriate amine (see the reported conversion of 12 to 23 
described in Scheme 3.3, page 73),
6a
 with or without Lewis acid catalysis, eventually 
provided racemic CP-99,994. These observations suggest that 12 is prone to racemization 
if it is heated or exposed to excess base and that the extent of racemization, under these 
conditions, may depend on variables that are difficult to regulate. A proposed mechanism 
for the racemization of 12 is shown in Scheme 3.10. 
 
 
Scheme 3.10. A proposed mechanism for the racemization of 12. 
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Oximation of 12 with methoxylamine by a significant modification of the 
reported procedure
13
 (ethanol instead of pyridine as the solvent) gave the corresponding 
oxime ether which was reduced stereoselectively to the amine 51 (Scheme 3.11). 
Reductive N-alkylation of 51 with 2-methoxybenzaldehyde followed by deprotection 
provided (+)-CP-99,994 (11 steps from benzaldehyde, 16.9% overall yield). 
 
 
Scheme 3.11. Synthesis of (+)-CP-99,994 employing ODVA reaction. 
 
We next investigated the synthesis of (2S,3R)-3-hydroxypipecolic acid. This 
particular diastereomer of 3-hydroxypipecolic acid has been the subject of numerous 
investigations and it continues to attract interest from synthetic chemists.
8a-f
 At the outset, 
it seemed reasonable that direct oxidation of the phenyl ring in the O-acetyl derivative of 
N-Boc-(2R,3R)-2-phenyl-3-hydroxypiperidine (ent-13), which was obtained by 
employing the enantiomer of catalyst 44, would lead us to the pipecolic acid target. 
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However, attempted oxidation
15
 (RuCl3/NaIO4) of this substrate invariably led to a 
mixture of products, none of which corresponded to the required carboxylic acid. 
Interestingly, a change in the N-protecting group
8c,16
 was beneficial. Accordingly, 
(2R,3R)-2-phenyl-3-hydroxypiperidine 52 was first converted to the N,O-bis 
(trifluoroacetyl) derivative and the trifluoroacetate ester was selectively replaced with an 
acetate to provide 53 (Scheme 3.12). Oxidation of the phenyl ring in 53,
 
with 
RuCl3/NaIO4, now proceeded smoothly to provide the corresponding carboxylic acid. 
Methanolysis of the trifluoroacetamide and the acetate in this intermediate gave (2S,3R)-
3-hydroxypipecolic acid (10 steps from benzaldehyde, 28.1% overall yield). 
 
Scheme 3.12. Synthesis of (2S,3R)-3-hydroxypipecolic acid from 52. 
 
3.4 Conclusions 
 In conclusion, we have achieved the synthesis of three representative members of 
the 2,3-disubstituted class of bioactive piperidines from the butenolide 45. The syntheses 
developed in this study are based on an organocatalytic vinylogous aldol reaction as the 
pivotal step. Notably, ketone 12 is also a starting material in the synthesis of spirocyclic 
NK-1 receptor antagonists.
14b,17
 The methodology presented here has potential use in the 
 85 
 
preparation of libraries of antagonists, related to the those described here, by variation of 
the aldehyde in the direct vinylogous aldol step.  
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3.5 Experimental section 
  All commercially available reagents were used without purification. All 
reactions requiring anhydrous conditions were performed under an atmosphere of dry 
nitrogen using oven dried glassware. Dichloromethane and tetrahydrofuran were 
distilled from CaH2 and sodium/benzophenone respectively. Commercial precoated 
silica gel plates were used for TLC. Silica gel for column chromatography was 230-
400 mesh. All melting points are uncorrected. Optical rotations were measured at the 
sodium D line on a digital polarimeter at ambient temperature. Compounds 45, 13, 
13a and 51a were prepared by literature methods. The conversion of 13a to (+)-L-
733,060 and of 51a to (+)-CP-99,994 was achieved by literature methods.  
 
(S)-5-[(R)-Hydroxy(phenyl)methyl]furan-2(5H)-one (45): 
OH
OO
Ph  
To the catalyst (20 mol %, 1.0 g) in a 25 mL round bottom flask was added benzaldehyde 
(970 µL, 9.14 mmol) followed by 2-(5H)-furanone 43 (1.28 mL, 18.3 mmol) and 
dichloromethane (5.0 mL). The mixture was stirred for 10 days at room temperature. The 
mixture was diluted with ethyl acetate (30 mL) and aqueous 2 N HCl (30 mL) was added. 
The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 
x 30 mL). The combined extracts were dried (Na2SO4), and concentrated. The residue 
was purified by flash chromatography (CH2Cl2/EtOAc, 10/1) to give 45 as a pale yellow 
solid (1.73 g, 74%). The diastereomeric composition (anti/syn = 8/1) was determined by 
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1
H NMR analysis of the crude product. The enantiomeric excess was determined by 
HPLC (Chiralpak AS-H, hexanes/2-propanol 90/10, 254 nm, t1 = 32.6 min (minor anti), 
t2 = 37.7 min (minor syn), t3 = 53.1 min (major syn), t4 = 70.5 min (major anti). Ee: > 
99% (anti)). In repeated experiments an ee range of 97 to > 99% was observed. 
IR: 3432, 3084, 2877, 2360, 2342, 1727, 1453, 1167, 1083, 1067, 1039, 820 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3): Anti diastereomer: δ 7.43-7.34 (m, 6H, ArH and 
COCH=CH), 6.19 (dd, 1H, J = 5.8, 1.9 Hz, COCH=CH), 5.19-5.18 (br m, 1H, 
CH=CHCH), 5.09 (br t, 1H, J = 4.1 Hz, ArCHOH), 2.25 (d, 1H, J = 3.8 Hz, OH); 
13
C 
NMR (75 MHz, CDCl3): δ 173.1 (C=O), 152.9 (CH=CH-C=O), 138.3  (ArC), 128.8 
(ArC), 128.6 (ArC), 126.1 (ArC), 123.2 (CH=CH-C=O), 86.6 (CH-O-C=O), 73.1 (CH-
OH); Syn diastereomer: δ 7.42-7.36 (m, 5H, ArH), 7.17 (dd, 1H, J = 5.8, 1.5 Hz, 
COCH=CH), 6.13 (dd, 1H, J = 5.8, 2 Hz, COCH=CH), 5.17 (apparent dt, 1H, J = 7.0, 1.5 
Hz, CH=CHCH), 4.71 (d, 1H, J = 7.0 Hz, ArCHOH), 2.78 (s, 1H, OH); 
13
C NMR (75 
MHz, CDCl3): δ 172.4 (C=O), 153.0 (CH=CH-C=O), 137.7 (ArC), 129.1 (ArC), 128.8 
(ArC), 126.8 (ArC), 123.1 (CH=CH-C=O), 86.9 (CH-O-C=O), 75.8 (CH-OH); MS 
(APCI, pos.): m/z 191.0 (M+1). 
 
5-Benzylidenefuran-2(2H)-one (49): 
 
Triethylamine (292 µL, 2.10 mmol) was added slowly to an ice cold solution of 45 (200 
mg, 1.05 mmol) in CH2Cl2, followed by the addition of methane sulfonyl chloride (122 
µL, 1.57 mmol). The reaction mixture was stirred for 1 h at 0 
o
C and water (20 mL) was 
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added at 0 
o
C. The mixture was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried (Na2SO4) and concentrated to provide 130 mg (72%) of 49 as a 
yellow oil.  
IR: 3064, 1705, 1630, 1492, 1214, 1164, 819, 699 cm
-1
; 
1
H-NMR (500 MHz, CDCl3) E 
isomer: δ 7.82 (1H, d, J = 5.6 Hz), 7.38-7.36 (5H, m), 6.80 (1H, s), 6.35 (1H, dd, J = 5.5, 
1.8 Hz),  Z isomer: δ 7.80 (2H, d, J = 7.4 Hz), 7.50 (1H, d, J = 5.3 Hz), 7.49-7.33 (3H, 
m), 6.23 (1H, d, J = 5.3 Hz), 6.04 (1H, s); MS (APCI pos.): m/z 192.3 (M+1). 
 
(S)-Dihydro-5-[(R)-(hydroxy(phenyl)methyl]furan-2(3H)-one (45): 
OH
OO
Ph  
Pd/C (10%, 75 mg) was added to a stirred solution of 45 (750 mg, 3.94 mmol) in EtOAc 
(10.0 mL). The reaction mixture was stirred for 4 h at room temperature under a balloon 
filled with H2. The mixture was filtered through Celite and the filter cake was washed 
with EtOAc (2 x 30 mL). The combined filtrates were concentrated under reduced 
pressure to provide 758 mg (99%) of 46 as a white solid (syn/anti = 8/1). This was pure 
by 
1
H NMR and was used in the next step without purification. 
IR: 3391, 1753, 1453, 1370, 1182, 1042, 992 cm
-1
; 
1
H NMR (500 MHz, CDCl3): Anti 
diastereomer: δ 7.39-7.32 (m, 5H, ArH), 5.13 (d, 1H, J = 2.7 Hz, CHOH), 4.72-4.65 (m, 
1H, CHCH2), 2.59-2.50 (m, 2H, CH2C=O, CHCH2), 2.5-2.4 (m, 1H, CH2C=O), 2.32-2.24 
(m, 1H, CH2CH-O), 1.97-1.90 (m, 1H, CH2CH-O); Visible peaks for the syn 
diastereomer: δ 4.65-4.60 (m, 1H, CHCH2), 2.06-2.01 (m, 1H, CH2CHO). 
13
C NMR (75 
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MHz, CDCl3): Anti diastereomer: δ 177.6 (CH2CO), 138.4 (ArC), 128.7 (ArC), 128.2 
(ArC), 126.0 (ArC), 83.3 (CH2CHO), 73.5 (CHOH), 28.6 (CH2CO), 20.7 (CH2CHO); 
Visible peaks for the syn diastereomer: δ 176.8 (CH2CO), 138.3 (ArC), 128.8 (ArC), 
128.2 (ArC), 127.0 (ArC), 83.4 (CH2CHO), 77.2 (CHOH), 28.5 (CH2CO), 24.0 
(CH2CHO); MS (EI pos): m/z: 193.1 (M+1).  
 
(S)-Dihydro-5-[(R)-(methylsulfonyl)(phenyl)methyl]furan-2(3H)-one (47): 
 
Triethyl amine (626 µL, 4.50 mmol) was added slowly to an ice cold solution of 46 (720 
mg, 3.75 mmol) in CH2Cl2, followed by the addition of methane sulfonyl chloride (349 
µL, 4.50 mmol). The reaction mixture was stirred for 1 h at 0 
o
C and water (20 mL) was 
added at 0 
o
C. The mixture extracted with CH2Cl2 (2 x 20 mL). The combined organic 
layers were dried (Na2SO4) and concentrated to provide 1.10 g (>99%) of 47 as a yellow 
oil. This was pure by 
1
H NMR and was used in the next step without purification. 
IR: 3027, 2938, 1775, 1351, 1171, 1031, 944, 912, 874, 836 cm
-1
; 
1
H NMR (500MHz, 
CDCl3): Anti diastereomer: δ 7.35 (m, 5H, ArH), 5.73 (d, 1H, J = 3.9 Hz, HC-
OSO2Me), 4.86-4.80 (m, 1H, CHCH2), 2.91 (s, 3H, CH3), 2.50-2.40 (m, 2H, CH2C=O), 
2.28-2.09 (m, 2H, CHCH2); Visible peaks for the syn diastereomer: δ 5.52 (d, 1H, J = 
5.7 Hz, HCOSO2Me), 2.89 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3): anti: δ 176.1, 
133.5, 129.6, 129.1, 126.9, 82.8, 80.4, 39.0, 27.7, 22.1; syn: δ 176.0, 133.7, 130.0, 129.2, 
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127.5, 84.3, 80.3, 39.3, 27.9, 24.2; MS (API-ES) m/z 270.4 (M
+
); HRMS (CI): 271.0640 
(271.0640 calc. for C12H15O5S, M + H).  
 
(S)-5-[(S)-Azido(phenyl)methyl]-dihydrofuran-2(3H)-one (48): 
N3
OO
Ph  
Sodium azide (1.22 g, 18.7 mmol) was added to the crude mesylate 47 (1.10 g, 4.07 
mmol) in DMF (5.0 mL) and the mixture was stirred at 80 
o
C for 4 h. The mixture was 
cooled to room temperature and EtOAc (30 mL) was added followed by water (30 mL). 
The resulting biphase was separated and the aqueous layer was extracted with EtOAc (2 x 
30 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated to 
provide 838 mg (>99%) of 48 as a yellow oil. This was pure by 
1
H NMR and was used in 
the next step without purification. 
IR: 2101, 1774, 1455, 1250, 1175, 1148, 1066, 990, 913 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3): Syn diastereomer: δ 7.44-7.35 (m, 5H, ArH), 4.71-4.61 (m, 1H, CH-CH2), 4.60 
(d, 1H, J = 5.9 Hz, CHN3), 2.48-2.34 (m, 2H, CH2C=O), 2.15-2.05 (m, 1H, CHCH2), 
2.05-1.95 (m, 1H, CHCH2); Visible peaks for the anti diastereomer: δ 4.90 (d, 1H, J = 
4.2 Hz, CHN3), 2.58-2.45 (m, CH2C=O), 2.25-2.15 (m, CHCH2); 
13
C NMR (75 MHz, 
CDCl3): Syn diastereomer: δ 176.2 (C=O), 134.5 (ArCipso), 129.2 (ArC), 127.8 (ArC), 
127.2 (ArC), 81.2 (O-CH), 68.5 (HCN3), 28.0 (CH2C=O), 24.6 (CH2CH); Visible peaks 
for the anti diastereomer: δ 176.4 (C=O), 134.6 (ArCipso), 129.1 (ArC), 129.0 (ArC), 
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81.4 (O-CH), 67.8 (HCN3), 28.1 (CH2C=O), 22.3 (CH2CH); MS (EI pos.): m/z 218.1 
(M+1); HRMS (APCI pos.): m/z 218.0972 (218.0930 calc. for C11H12N3O2 (M+H)). 
 
(5S,6S)-5-Hydroxy-6-phenylpiperidin-2-one (22): 
N
H
OH
PhO
 
To a stirred solution of 48 (810 mg, 4.24 mmol) in methanol (5.0 mL) was added K2CO3 
(160 mg, 1.16 mmol) followed by Pd/C (10%, 81 mg). The reaction mixture was stirred 
for 4 h at room temperature under a balloon filled with H2 and then filtered through a pad 
of Celite. The filter cake was washed with MeOH (2 x 30 mL) and the combined filtrates 
were concentrated under reduced pressure to provide a yellow gum. This was purified by 
flash chromatography on silica gel (CH2Cl2/MeOH, 95/5 as the eluant) to provide 543 mg 
(76%) of cis-22 as a fluffy white solid and 91.0 mg (13 %) of trans-22 as a white solid. 
Cis diastereomer: Mp: 99 
o
C (lit.
6b
 mp. 92 
o
C); IR: 3360, 3197, 2945, 1643, 1461, 1399, 
1351, 1318, 1197, 1069, 986, 942 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.44-7.41 (m, 2H, 
ArH), 7.37-7.33 (m, 3H, ArH), 5.85 (br s, 1H, CONH), 4.67 (d, 1H, J = 2.7 Hz, CHAr), 
4.08 (br s, 1H, CHOH), 2.76-2.69 (m, 1H, CH2C=O), 2.41-2.37 (m, 1H, CH2C=O), 2.15-
2.13 (m, 1H, CHCH2), 2.04-2.01 (m, 1H, CHCH2), 1.69 (s, 1H, OH); 
13
C NMR (75 MHz, 
CDCl3): δ 172.3 (C=O), 137.9 (ArCipso), 129.2 (ArC), 128.7 (ArC), 127.0 (ArC), 66.2 
(CHOH), 61.9 (CHAr), 26.7 (CHCH2), 26.07 (CH2C=O); MS (APCI, pos.) m/z 192.1 
(M+1); HRMS (EI): 191.0950 (191.0946 calc. for C11H13NO2 (M+H)); [α]D
23
 = +55.3 (c 
1.06, CH2Cl2), lit. [α]D
25
 = +52.0 (c 1.1, CH2Cl2).
6b
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Trans diastereomer: IR: 3237, 2364, 1631, 1581, 1485, 1446, 1349, 1333, 1175, 1076, 
945, 801 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 7.45-7.40 (m, 2H, ArH), 7.40-7.35 (m, 3H, 
ArH), 5.70 (br s, 1H, CONH), 4.69 (d, J = 2.8 Hz, 1H, CHAr), 4.10 (br s, 1H, CHOH), 
2.77 (ddd, 1H, J = 18.0, 11.9, 6.5 Hz, CH2CO), 2.43 (ddd, 1H, J = 18.0, 6.2, 2.8 Hz, 
CH2CO), 2.19-2.15 (m, 1H, CHCH2), 2.07-2.03 (m, 1H, CHCH2), 1.47 (br t, 1H, J = 1.5 
Hz, OH); 
13
C NMR (75 MHz, CDCl3): δ 172.2 (C=O), 137.8 (ArCipso), 129.2 (ArC), 
128.8 (ArC), 127.0 (ArC), 66.3 (CHOH), 61.9 (CHAr), 26.7 (CHCH2), 26.1 (CH2C=O); 
MS (APCI pos.): m/z 192.3 (M
+); [α]D
23
 = +26.0 (c 1.0 , MeOH); lit. [α]D
23
 = +31.6 (c 
0.75, MeOH).
18 
 
(2S,3S)-2-Phenylpiperidin-3-ol (50): 
N
H
OH
Ph
 
Borane-THF complex (4.70 mL, 4.68 mmol) was added to cis-22 (300 mg, 1.56 mmol), 
and the mixture was heated to reflux for 5 h. The mixture was cooled to 0 
o
C, aqueous 
HCl (3 M, 12.0 mL) was added and the mixture was stirred for 30 min. at room 
temperature. The mixture was then concentrated to dryness under reduced pressure and 
the residue was basified with 5% aqueous NaOH at 0 
o
C to pH~10. The resulting mixture 
was extracted with EtOAc, dried (Na2SO4) and concentrated to provide 50 as a white 
solid (267 mg, 96%). This was pure by 
1
H NMR and was used in the next step without 
purification. 
 93 
 
Mp: 90-93 
o
C; IR: 3274, 2926, 2851, 1447, 1323, 1089, 1054, 1053, 989 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3):  δ 7.35-7.32 (m, 3H, ArH), 7.32-7.24 (m, 2H, ArH), 3.86 (br s, 1H, 
CHAr), 3.78 (br s, 1H, CHOH), 3.22-3.19 (m, 1H, NCH2), 2.81 (dt, 1H, J = 12.1, 2.8 Hz, 
NCH2), 2.02-1.92 (m, 1H, CHCH2), 1.89-1.84 (m, 1H, CHCH2), 1.74-1.67 (m, 1H, 
CH2CH2N), 1.52-1.48 (m, 1H, CH2CH2N); 
13
C NMR (75 MHz, CDCl3): δ 142.0 
(ArCipso), 128.5 (ArC), 127.3 (ArC), 126.6 (ArC), 68.9 (CHOH), 65.0 (CHAr), 47.5 
(NCH2), 32.0 (CHCH2), 19.9 (CH2CH2N); MS (APCI, pos.): m/z 178.1 (M+1); HRMS 
(EI): 177.1153 (177.1154 calcd for C11H15NO); [α]D
23
 = +66.45 (c 0.62, CHCl3). 
 
(2S,3S)-tert-Butyl 3-hydroxy-2-phenylpiperidine-1-carboxylate (13): 
N
OH
Ph
O OtBu  
To a solution of 50 (500 mg, 2.82 mmol) in CH2Cl2 (5.0 mL) were added di-tert-butyl 
dicarbonate (616 mg, 2.82 mmol), 4-(dimethylamino)pyridine (25 mg, 0.20 mmol) and 
triethylamine (431 µL, 3.10 mmol) at 0 
o
C. The solution was stirred at room temperature 
for 3 h, saturated aqueous NH4Cl was added and the resulting mixture was extracted with 
CH2Cl2 (2 x 20 mL). The combined organic layers were dried (Na2SO4) and 
concentrated. Purification of the residue by flash chromatography on silica gel 
(hexanes/EtOAc, 7/3) afforded 663 mg (85%) of 13 as colorless oil. 
IR: 3452, 2937, 1661, 1413, 1362, 1255, 1175, 1141, 1074, 1024, 962, 871 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3): δ 7.45 (d, 2H,  J = 7.6 Hz, ArH), 7.34 (t, 2H, J = 7.6 Hz, ArH), 
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7.28-7.26 (m, 1H, ArH), 5.33 (d, 1H, J = 5.4 Hz, CHAr), 4.1-4.06 (m, 1H, CHOH ), 4.01 
(dd,  J = 4.9 Hz, 13.2 Hz, 1H, NCH2), 3.04 (dt, J = 3.9 Hz, 13.2, 1H, NCH2), 1.84-1.67 
(m, 3H, CH2CH2), 1.67-1.62 (m, 1H, CH2CH2), 1.58 (s, 1H, OH),  1.37 (s, 9H, C(CH3)3) ;
 
13
C NMR (500MHz, CDCl3): δ 155.4 (C=O), 138.4 (ArCipso), 128.4 (ArC), 127.2 (ArC), 
79.9 (C(CH3)3), 70.1 (CHOH), 59.3 (CHAr), 39.5 (CH2N), 28.3 ((CH3)3, 27.7 (CHCH2), 
23.1 (NCH2CH2); MS (APCI, pos.): m/z 178.1 ((M-Boc)+1); [α]D
23
 = +42.3 (c 1.0, 
CHCl3), lit. [α]D
24
 = +42.6 (c 0.54, CHCl3).
6b
 
 
(2S,3S)-tert-Butyl-3-[3,5-bis(trifluoromethyl)benzyloxy]-2-phenylpiperidine-1-
carboxylate (13a): 
 
To a solution of 13 (60 mg, 0.22 mmol) in DMF/THF (3:1, 1.0 mL) under N2 at 0 
o
C was 
added sodium hydride (95%, 16 mg, 0.65 mmol). The mixture was stirred at room 
temperature for 30 min. and 3,5-bis(trifluoromethyl)benzyl bromide (0.10 g, 0.33 mmol) 
was added at 0 
o
C. The mixture was stirred 16 h at room temperature, after which water 
(5.0 mL) added at 0 
o
C and the mixture was extracted with Et2O (2 x 10 mL) The 
combined organic layers were washed with brine, dried (Na2SO4) and concentrated. The 
residue was purified by flash chromatography on silica gel (hexanes/EtOAc, 9/1) to give 
57 mg (52%) of 13a as colorless oil. 
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IR: 2939, 1686, 1411, 1357, 1276, 1175, 1128, 885 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 
7.77 (s, 1H, ArH), 7.71 (s, 2H, ArH), 7.55 (d, 2H, J = 7.7 Hz, ArH), 7.33 (t, 2H, J = 7.7 
Hz, ArH), 7.27-7.25 (m, 1H, ArH), 5.69 (br s, 1H, CHAr), 4.73 (AB system, 2H, J = 12.6 
Hz, CH2Ar), 3.96-3.90 (m, 1H, NCH2 or CHO), 3.90-3.86 (m, 1H, NCH2 or CHO), 2.77 
(dt, J = 13.1, 3.2 Hz, 1H, NCH2), 2.01-1.96 (m, 2H, CHCH2), 1.74-1.70 (m, 1H, 
CH2CH2N),  1.70-1.60 (m, 1H, CH2CH2N),  1.46 (s, 9H, C(CH3)3) ;
 13
C NMR (75 MHz, 
CDCl3): δ 155.3 (C=O), 141.0 (ArC), 138.01 (ArC), 131.6 (q, J = 33.3 Hz, CF3), 128.4 
(ArC), 128.3 (ArC), 127.2 (br, ArC), 127.1 (ArC), 125.1 (ArC), 121.5-121.4 (br, ArC), 
80.1 (C(CH3)3), 78.7 (CH-O), 69.2 (CH2Ar), 55.5 (CHAr), 39.2 (NCH2), 28.4 (C(CH3)3), 
25.9 (CHCH2), 24.2 (CH2CH2N); MS (APCI, pos.): m/z 404.2 ((M-Boc)+1); [α]D
23
 = 
+39.1 (c 1.0, CHCl3), lit. [α]D
25
 = +27.9 (c 0.8, CHCl3).
6e
 
 
(2S,3S)-3-[3,5-bis(trifluoromethyl)benzyloxy]-2-phenylpiperidine ((+)-L-733,060): 
N
H
O
Ph
CF3
CF3
 
To a solution 13a (46 mg, 0.09 mmol) in CH2Cl2 (1.0 mL) was added trifluoroacetic acid 
(70 µL, 0.91 mmol) at 0 
o
C. The mixture was stirred at room temperature for 18 h and 
10% aqueous NaOH was added at 0 
o
C. After extraction with CH2Cl2, the combined 
organic layers were washed with brine, dried (Na2SO4), filtered and concentrated to 
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afford 34 mg (92%) of (+)-L-733,060 as a colorless oil that was pure by 
1
H NMR (500 
MHz). 
IR: 2936, 2858, 1374, 1342, 1276, 1174, 1126, 883, 837 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3): δ 7.69 (s, 1H, ArH), 7.44 (s, 2H, ArH), 7.37 (br d, 2H, J = 7.3 Hz, ArH), 7.32 
(br t, J = 7.2 Hz, 2H, ArH), 7.27 (m, 1H, ArH), 4.52 (d, 1H, J = 12.5 Hz, CH2Ar), 4.14 
(d, 1H, J = 12.5 Hz, CH2Ar), 3.85 (s, 1H, CHAr), 3.68 (s, 1H, CHOCH2Ar), 3.30-3.27 
(m, 1H, NCH2), 2.85 (dt, J = 12.4, 2.8 Hz, 1H, NCH2), 2.22 (d, 1H, J = 13.9 Hz, 
CHCH2), 1.89-1.82 (m, 1H, CHCH2), 1.77-1.70 (m, 1H, CH2CH2CH-O), 1.54-1.51 (m, 
1H, CH2CH2CH-O);
 13
C NMR (75 MHz, CDCl3): δ 141.4 (ArC), 141.1 (ArC), 131.33 (q, 
J = 33.2 Hz, CF3), 128.2 (ArC), 127.5 (ArC), 127.3 (ArC), 126.8 (ArC), 125.1 (ArC), 
121.5-121.2 (m, ArC), 77.1 (CH-O), 70.1 (CH2Ar), 64.2 (CHAr), 46.9 (NCH2), 28.4 
(CH2CH-O),  20.3 (CH2CH2N); MS (APCI pos.): m/z 404.4 (M
+
); HRMS (CI): m/z 
404.1447 (404.1449 calcd for C20H20F6NO, M+H); [α]D
23
 = +48.6 (c 0.51, CHCl3); lit. 
[α]D
24
 = +31.7 (c 0.5, CHCl3)
6e
. 
 
(S)-tert-Butyl-3-oxo-2-phenylpiperidine-1-carboxylate (12): 
N
O
Ph
O OtBu  
Dess-Martin periodinane (1.07 g, 2.50 mmoles) was added to a solution of alcohol 13 
(0.14 g, 0.50 mmol) in CH2Cl2 (3.0 mL) and the mixture was stirred at room temperature 
for 1 h. Saturated aqueous sodium bicarbonate (10 mL) was added, the organic layer was 
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separated and the aqueous layer was extracted with CHCl3 (3 x 30 mL). The combined 
organic layers were washed with brine (30 mL), dried (Na2SO4), and concentrated. The 
residue was purified by flash chromatography (hexanes/EtOAc, 8/2) to give 106 mg 
(76%) of 12 as a pale yellow liquid. 
IR: 2974, 1690, 1401, 1361, 1247, 1154 (br), 1105, 1031, 967 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3): δ 7.37-7.20 (m, 5H, ArH), 5.65 (br s, 1H, CHAr), 4.08 (br s, 1H, CH2N), 3.34-
3.30 (br m, 1H, CH2N), 2.51-2.40 (m, 2H, CH2C=O), 1.98-1.88 (m, 2H, CH2CH2C=O), 
1.43 (br s, 9H, C(CH3)3);
 13
C NMR (75 MHz, CDCl3): δ 205.5 (CH2C=O), 155.0 (N-
C=O), 135.6 (ArC), 128.9 (ArC), 127.6 (ArC), 125.4 (ArC), 80.7 (C(CH3)3), 65.9 (br, 
CHAr), 40.1 (br, NCH2), 37.3 (CH2C=O), 28.2 (C(CH3)3), 22.8 (CH2CH2N); HRMS (EI 
pos.): 275.1525 (275.1521 calcd for C16H21NO3); HPLC: Chiralpak AD-H, hexanes/2-
propanol 99/1, 254 nm, tmajor = 35.7 min, tminor = 37.6 min.; ee = 96% ee. 
 
(2S,3S)-tert-Butyl 3-amino-2-phenylpiperidine-1-carboxylate (51): 
N Ph
O OtBu
NH2
 
To a stirred solution of ketone 12 (60 mg, 0.22 mmoles) in ethanol (0.50 mL) at room 
temperature, was added anhydrous pyridine (26 μL, 0.33 mmol) followed by 
methoxylamine hydrochloride (27 mg, 0.33 mmol) and the mixture was stirred at room 
temperature for 30 min. Saturated aqueous NH4Cl (10 mL) was added, the mixture was 
stirred for 30 min, and then extracted with diethyl ether (3 x 30 mL). The combined 
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organic layers were dried (Na2SO4), and concentrated to provide the crude oxime methyl 
ether of 51 (70 mg). This was treated with BH3-THF (1 M soln. in THF, 0.65 mL, 0.63 
mmoles) under N2 and the solution was stirred at 50 
o
C for 4h. Saturated aqueous NH4Cl 
(10 mL) was added and the mixture was extracted with CHCl3 (3 x 30 mL), dried 
(Na2SO4), and concentrated. The crude product was purified by flash chromatography on 
silica gel (CH2Cl2/MeOH, 9/1) to provide 40 mg (67%) of 51 as pale yellow oil. This was 
pure by 
1
H NMR and was used in the next step without purification. 
IR: 2931, 1682, 1407, 1362, 1252, 1147, 868 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.44 
(d, 2H, J = 7.3 Hz, ArH), 7.31-7.28 (m, 2H, ArH), 7.26-7.23 (m, 1H, ArH), 5.20 (d, 1H, J 
= 6.0 Hz, CHAr), 4.01 (br d, 1H, J = 10.9 Hz, CHNH2), 3.20-3.11 (m, 2H, NCH2), 1.88-
1.65 (m, 4H, CH2CH2CH), 1.45 (br s, 2H, NH2), 1.36 (s, 9H, C(CH3)3);
 
13C NMR (75 
MHz, CDCl3): δ 155.4 (CO2
t
Bu), 139.1 (ArC), 129.4 (2 × ArC), 128.2 (2 × ArC), 127.2 
(ArC), 79.7 (OC(CH3)3), 60.6 (NCH), 51.2 (CHNH2), 39.8 (NCH2), 29.2 (NH2CHCH2), 
28.3 (C(CH3)3), 24.4 (NCH2CH2); MS (EI pos.): m/z 277.2 (M + 1). 
 
(2S,3S)-tert-Butyl 3-(2-methoxybenzylamino)-2-phenylpiperidine-1-carboxylate 
(51a): 
N
H
N
Ph
OCH3
O OtBu  
To a solution of amine 51 (16 mg, 0.06 mmol) in THF (1.0 mL) was added 2-
methoxybenzaldehyde (21 μL, 0.17 mmol) and the mixture was stirred at room 
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temperature for 22 h. The solvent was removed under reduced pressure and the residue 
was dissolved in methanol (1.0 mL). Sodium borohydride (13 mg, 0.35 mmoles) was 
added to this solution and the mixture was stirred at room temperature for 3 h. Saturated 
aqueous NaHCO3 (pH~8) was added and the mixture was extracted with CH2Cl2 (3 x 10 
mL). The combined organic layers were dried (Na2SO4), and concentrated. The crude 
product was purified by flash chromatography on silica gel (CH2Cl2/ EtOAc, 9/1) to 
provide 18 mg (78%) of 51a as pale yellow oil. This was pure by 
1
H NMR and was used 
in the next step without purification. 
IR: 2933, 1685, 1494, 1457, 1407, 1359, 1241, 1178, 1144, 1030 cm
-1
; 
1
H NMR (500 
MHz, CDCl3): δ 7.58 (d, 2H, J = 7.3 Hz, ArH), 7.33-7.28 (m, 2H, ArH), 7.26-7.18 (m, 
3H, ArH), 6.89 (t, 1H, J = 7.4 Hz, ArH), 6.81 (d, 1H, J = 8.5 Hz, ArH), 5.47 (s, 1H, 
CHAr), 3.95 (d, 1H, J = 11.1 Hz, NCH2), 3.77 (AB system, 2H,  J = 13.4 Hz, CH2Ar), 
3.71 (s, 3H, OCH3), 3.07-3.03 (m, 1H, CHNH), 2.97 (dt, 1H, J = 13.0, 2.3 Hz, NCH2), 
1.85-1.75 (m, 3H, CH2CHNH), 1.66-1.53 (m, 2H, CH2CH2N), 1.41 (s, 9H, C(CH3)3);
 13
C 
NMR (75 MHz, CDCl3): δ 157.5 (CO), 155.2 (ArC), 139.2 (ArC), 129.5 (ArC), 129.2 
(ArC), 128.4 (ArC), 128.1 (ArC), 128.0 (ArC), 126.9 (ArC), 120.4 (ArC), 110.1 (ArC), 
79.6 (C(CH3)3), 57.2 (CHAr), 55.0 (CHNH, OCH3), 46.6 (CH2Ar), 39.5 (NCH2), 28.4 
(C(CH3)3, 26.8 (CH2CHNH), 24.3 (CH2CH2N); MS (EI pos.): m/z 397.5 (M+1); HRMS 
(EI): m/z 396.2412 (396.2413 calcd for C24H32N2O3); HPLC (Chiralpak OD-H, 
hexanes/2-propanol 90/10, 210 nm, tminor = 4.64 min, tmajor = 5.20 min; ee = 93.4%. 
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(2S,3S)-N-(2-Methoxybenzyl)-2-phenylpiperidin-3-amine ((+)-CP-99,994): 
N
H
H
N
Ph
OCH3
 
To a solution of 51a (18 mg, 0.05 mmol) in MeOH (0.50 mL) was added 1:1 mixture of 
conc. aqueous HCl and methanol (1.0 mL) at 0 
o
C and the mixture was stirred at room 
temperature for 22 h. Saturated aqueous NaHCO3 was added (pH~8), and the mixture 
was extracted with CH2Cl2 (3 x 10 mL). The combined extracts were dried (Na2SO4), and 
concentrated to give 12 mg (92%) of CP-99,994 as a pale yellow oil that was pure by 
1
H 
NMR (500 MHz). 
IR: 2935, 2846, 1647, 1595, 1492, 1451, 1239, 1111, 1027, 743 cm
-1
; 
1
H NMR (500 
MHz, CDCl3): δ 7.30-7.12 (m, 6H, ArH), 6.97 (d, 1H, J = 7.3 Hz, ArH), 6.80 (t, 1H, J = 
7.3 Hz, ArH), 6.67 (d,  J = 8.2 Hz, 1H, ArH), 3.87 (s, 1H, CHAr), 3.67 (d, 1H, J = 13.9 
Hz, CH2Ar), 3.44 (s, 3H, OCH3), 3.41 (d, 1H, J = 13.9 Hz, CH2Ar), 3.28-3.25 (m, 1H, 
CHNH), 2.82-2.76 (m, 2H, NCH2), 2.14 (br d, 1H, J = 13.5 Hz, CH2CHNH), 1.95-1.91 
(m, 1H, CH2CH2NH), 1.77 (br s, 2H, NH), 1.63-1.57 (m, 1H, CH2CHNH), 1.39 (br d, 
1H,  J = 13.1 Hz, CH2CH2NH);
 13
C NMR (75 MHz, CDCl3): δ 157.6 (ArC), 142.4 (ArC), 
129.5 (ArC), 128.2 (ArC), 128.1 (ArC), 127.8 (ArC), 126.5 (ArC), 126.3 (ArC), 119.9 
(ArC), 109.7 (ArC), 63.9 (CHAr), 54.7 (NCH), 54.6 (OCH3), 47.7 (CH2Ar), 46.7 
(NCH2), 28.2 (CH2CHN), 20.3 (CH2CH2NH); MS (APCI pos.): m/z: 297.4 (M+1); 
HRMS (EI): 296.1898 (296.1889 calcd for C19H24N2O, M
+); [α]D
23
 = +68.0 (c 1.1, 
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CHCl3); lit. [α]D
20
 = +67.2 (c 1, CHCl3);
13
 HPLC (Chiralpak OD-H, hexanes/2-propanol 
90/10, 210 nm, tmajor = 6.07 min, tminor = 8.94 min; ee = 94.8%. 
 
N-Trifluoroacetyl-(2S,3R)-3-acetoxy-2-phenylpiperidine (53): 
N Ph
O CF3
O
O
CH3
 
To an ice cold solution of the aminoalcohol 52 (ent-50, 500 mg, 2.82 mmol; prepared as 
described for 50, but with the enantiomer of catalyst 44) in CH2Cl2 (30.0 mL) containing 
Et3N (2.30 mL, 16.9 mmol) and 4-(dimethylamino)pyridine (17 mg, 0.14 mmol) was 
added  triflouroacetic anhydride (1.60 mL, 11.3 mmol ). The solution was stirred at room 
temperature for 12 h, water was added and the solution was extracted with CH2Cl2 and 
the combined extracts were dried (Na2SO4), and concentrated. The residue was dissolved 
in THF (30.0 mL), K2CO3 (770 mg, 5.57 mmol) was added and the mixture was stirred 
for 36 h at room temperature. Water was added and the mixture was extracted with 
CH2Cl2 and the combined extracts were dried (Na2SO4) and concentrated. The residue 
was purified by flash chromatography (hexanes/EtOAc, 7/3) to provide 715 mg (93%) of 
the trifluoroacetamide derivative of 52. This was dissolved in CH2Cl2 (30.0 mL), Et3N 
(1.57 mL, 11.3 mmol) and 4-(dimethylamino)pyridine (15 mg, 0.12 mmol) were added 
and the solution was cooled to 0 
o
C. Acetic anhydride (530 μL, 5.19 mmol) was added 
and the reaction mixture was stirred at room temperature for 12 h. Water was added and 
the mixture was extracted with CH2Cl2. The combined extracts were dried (Na2SO4), and 
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concentrated. The crude product was purified by flash chromatography (hexanes/ EtOAc, 
8/2) to provide 795 mg (89%) of 53 as a pale yellow oil. 
IR: 1743, 1687, 1451, 1370, 1235, 1193, 1045 cm
-1
; 
1
H NMR (500 MHz, CDCl3): Major 
rotamer: δ 7.49-7.26 (m, 5H, ArH), 5.99 (d, 1H,  J = 5.7 Hz, CHAr),  5.25-5.20 (m, 1H, 
CHOAc), 3.83 (br d, 1H,  J = 14.0 Hz, NCH2), 3.19-3.13 (m, 1H, NCH2),  2.17-2.11 (m, 
2H, CH2CHOAc), 2.0 (s, 3H, COCH3), 1.85-1.83 (m, 2H, CH2CH2N);
 13
C NMR (75 
MHz, CDCl3): δ 169.6 (COCH3), 135.4 (COCF3), 128.9 (ArC), 128.7 (ArC), 128.0 
(ArC), 128.0 (ArC), 127.8 (ArC), 116.6 (q, J = 288.0 Hz, CF3), 55.5(CHAr), 41.2 (q, J = 
3.4 Hz, CH2N), 24.9 (CH2CH-O), 23.9 (CH3), 21.1 (CH2CH2N); Minor rotamer: 
1
H 
NMR (500 MHz, CDCl3), visible peaks: 5.55 (d,  J = 5.3 Hz, 1H, CHAr), 4.37 (d,  J = 
11.8 Hz, 1H, CH2N), 2.75 (dt, 1H, J = 13.3, 4.1 Hz, NCH2N). 
13
C NMR (75 MHz, 
CDCl3), visible peaks: δ 169.7 (COCH3), 156.5 (q, J = 36.1 Hz, CF3), 135.0 (COCF3), 
72.4 (CH-O), 70.6 (CHO), 57.7 (CHAr), 38.8 (CH2CH-O), 23.5 (CH3), 21.1 (CH2CH2N); 
MS (APCI pos.): m/z 316.1 (M+1). 
 
(2R,3R)-3-Hydroxypiperidine-2-carboxylic acid: 
N
H
OH
COOH
 
To a mixture of 53 (0.15 g, 0.48 mmol) in carbon tetrachloride (0.75 mL), acetonitrile 
(0.75) mL and water (1.1 mL), were added sodium periodate (1.53 g, 7.13 mmol) and 
ruthenium chloride (5.0 mg, 0.02 mmol) and the mixture was stirred vigorously at 
ambient temperature for 20 h. The mixture was filtered through a pad of Celite and the 
 103 
 
residue was rinsed several times with CH2Cl2. The black filtrates were combined, dried 
(Na2SO4) and concentrated. The residue obtained was dissolved in methanol (5.0 mL), 
K2CO3 (393 mg, 2.84 mmol) was added and the mixture was stirred at room temperature 
for 12 h. The resulting solution was concentrated and the residue was dissolved in 
aqueous 1 N HCl (1.0 mL).  This solution was applied to a column of Dowex 50Wx8 
resin (200-400 dry mesh) and the column was eluted with deionized water (250 mL) 
followed by 5% aqueous ammonia. The ninhydrin positive fractions were combined and 
concentrated to provide 40 mg (58%) of (2R,3R)-3-hydroxypiperidine-2-carboxylic acid 
as a white solid. 
Mp. 231-235 
o
C (lit.
8a
 mp 233-238 
o
C); IR: 3600-2859 (br), 1618 (br), 1461, 1399, 1312, 
1205, 1137, 1083, 1042, 996 cm
-1
; 
1
H NMR (500 MHz, D2O): δ 4.44 (s, 1H, CHCOOH), 
3.60 (d, 1H,  J = 1.4  Hz, CH-OH), 3.37-3.33 (m, 1H, CH2NH), 2.94 (dt, 1H,  J = 3.5, 
12.9  Hz, CH2NH), 1.95-1.84 (m, 2H, CH2CHOH), 1.76-1.66 (m, 2H, CH2CH2N);
 13
C 
NMR (75 MHz, CDCl3): δ 172.3 (COOH), 64.1 (CH-OH), 62.2 (CHCOOH), 43.6 
(CH2N), 28.7 (CH2CHOH), 15.9 (CH2CH2N); MS (APCI pos.): m/z 146.1 (M+H); [α]D
23
 
= -53.5 (c 0.6, H2O); lit. [α]D
24
 = - 52.8 (c 0.6, H2O).
 8f
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3.8 Selected HPLC chromatograms 
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18-Aug-2011  16:26:15AD-H 99 hex 1ipa 210nm 90 min
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
A
U
0.0
1.0e-1
2.0e-1
3.0e-1
4.0e-1
5.0e-1
6.0e-1
7.0e-1
8.0e-1
9.0e-1
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
EKP-05-65A Diode Array 
Range: 1.85
Height
Area%
2.10
95.05
2.85
Area
28197.39
1276655.50
38223.31
Height
43493
1847864
49935
Time
26.27
34.00
35.75
1847864
43493
49935
minor
major
 
05-Sep-2011  11:29:46AD-H 99 hex 1ipa 210nm 60 min
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
A
U
0.0
1.0e-1
2.0e-1
3.0e-1
4.0e-1
5.0e-1
6.0e-1
7.0e-1
8.0e-1
9.0e-1
1.0
1.1
1.2
1.3
1.4
EKP-05-25B (Recemic) Diode Array 
Range: 1.546
Height
Area%
0.54
52.45
47.00
Area
10749.14
1038342.94
930411.44
Height
23315
1536926
1269098
Time
12.69
34.72
36.27
1536926
23315
1269098
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03-Sep-2011  17:34:22OD-H 90 hex 10ipa 210nm 60 min
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00
A
U
0.0
1.0e-1
2.0e-1
3.0e-1
4.0e-1
5.0e-1
6.0e-1
7.0e-1
8.0e-1
9.0e-1
1.0
1.1
EKP-05-72A(3rd run) Diode Array 
Range: 1.248
Height
Area%
1.61
1.46
94.24
2.69
Area
7592.75
6903.24
445281.91
12705.33
Height
30845
51730
1234624
30998
Time
3.62
4.90
6.24
9.75
1234624
51730
30845 30998
minor
major
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CHAPTER 4 
 
Synthesis of (+)-Febrifugine and a Formal Synthesis of 
 (+)-Halofuginone Employing an Organocatalytic Direct Vinylogous  
Aldol Reaction 
 
 
 
This Chapter is based on the following publication:  
Pansare, S. V.; Paul, E. K. Synthesis 2013, 45, 1863-1869. 
Contributions of authors  
S. V. Pansare: research supervisor, manuscript preparation.  
E. K. Paul: experimental work, manuscript preparation.  
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4.1 Introduction 
The prevalence of malaria in tropical regions and the need for new medicines to 
combat malaria have resulted in a persistent, and often challenging, search for new 
antimalarial agents.
1
 In this context, febrifugine (1, Figure 4.1) and halofuginone (2) have 
attracted considerable interest due to their pronounced antimalarial activity.
2
 In solution, 
febrifugine (1) is gradually converted to isofebrifugine (3) which is less potent, but 
exhibits antimalarial activity similar to febrifugine.
2d
 The asymmetric synthesis of 
febrifugine
3
 continues to be actively investigated and the reported syntheses often 
showcase new methodology for stereoselective construction of the 2,3-disubstituted 
piperidine ring in the targets. Only two asymmetric syntheses of halofuginone
3a,4
 are 
reported. Febrifugine and halofuginone also have numerous other applications which 
have contributed to a continued interest in these alkaloids. Notably, in addition to its 
antimalarial properties, halofuginone is used as an antiprotozoal agent in poultry
5
 and it is 
also an antiangiogenic agent.
6
 It has been approved for the treatment of scleroderma and 
it is active against oestrogen-deficient osteoporosis in mice.
7
 Recently, the molecular 
mechanism of action of febrifugine and halofuginone in mice has been determined.
8
 
These studies highlighted the importance of structural analogs of febrifugine in the 
treatment of multiple sclerosis, scleroderma and rheumatoid arthritis. Hence, an 
important consideration in devising a synthesis of the title compounds is the flexibility of 
the approach for making analogs of febrifugine. 
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Figure 4.1. (+)-Febrifugine (1), (+)-halofuginone (2) and isofebrifugine (3). 
 
4.2 Known synthetic routes to (+)-Febrifugine 
The following summary provides an overview of selected reported syntheses of           
(+)-febrifugine from 2009 onwards. 
 
4.2.1 The Sudalai synthesis of (+)-Febrifugine 
 
Sudalai and coworkers reported
3f 
an enantioselective synthesis of (+)-febrifugine. 
The synthesis started from the commercially available 1,5-hexadien-3-ol 4, which 
undergoes Claisen-Johnson rearrangement to afford the ester 5 (Scheme 4.1). The Os-
catalyzed regioselective ADH of 1,4-dienic ester 5 using (DHQ)2-PHAL as the chiral 
ligand provided hydroxyl lactone 6. The secondary alcohol in 6 was protected as its 
mesylate followed by displacement of the mesylate, with inversion of configuration, by 
azide anion gave the azido butyrolactone 7. Under Staudinger conditions, the azide 7 
undergoes reductive cyclization to the piperidinone 8. Reduction of the lactam in 8 using 
LiAlH4 provided the corresponding piperidine, which was treated with benzyl 
chloroformate. Subsequent benzylation of the secondary alcohol using benzyl bromide 
afforded the key intermediate 9. The regioselective bromohydroxylation of 9 using NBS 
provided the terminal halide 10 as a diastereomeric mixture (dr = 1.5:1). This was treated 
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with 4-hydroxyquinazoline in the presence of KOH followed by the oxidation of 
secondary alcohol to ketone using Dess-Martin periodinane to provide protected 
febrifugine 11. Deprotection of 11 (6 M HCl) and subsequent neutralization provided (+)-
febrifugine (12 steps from 4, 15% overall yield). 
 
 
Scheme 4.1. Synthesis of (+)-febrifugine by Sudalai. 
 
4.2.2 The Lin synthesis of (+)-Febrifugine 
In 2009, Lin and coworkers reported
3b 
an asymmetric total synthesis of (+)-
febrifugine. The synthesis began with the Swern oxidation of 12 to afford the aldehyde, 
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which was treated with tert-butanesulfinamide to provide the imine 13 (Scheme 4.2). The 
SmI2-mediated reductive cross-coupling reaction of imine 13 with the aldehyde 14 under 
-78 
o
C afforded the amido alcohol 15 in good yield and diastereoselectivity 
(93.5:4.0:2.0:0.5). Protection of the hydroxyl group in 15 as the benzyl ether and 
subsequent treatment with m-CPBA gave the sulfonamide 16. After removal of the silyl 
group in 16 with TBAF, mesylation of the hydroxyl group followed by base-induced 
cyclization provided the N-sulfonyl piperidine 17. Treatment of 17 with p-toluenesulfonic 
acid in methanol to afforded the diol 18. Monotosylation of 18 followed by base 
mediated cyclization provided the epoxide 19. Opening the epoxide with the anion of         
4-hydroxyquinazoline followed by the oxidation of the secondary alcohol using Dess-
Martin periodinane gave protected febrifugine. This was deprotected using 6 M HCl to 
provide (+)-febrifugine (14 steps from 12, 23.5% overall yield). 
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Scheme 4.2. Synthesis of (+)-febrifugine by Lin. 
 
4.2.3 The Evans synthesis of (+)-Febrifugine 
 
Evans and coworkers reported
3a 
an enantioselective synthesis of (+)-febrifugine. 
The synthesis started from 4-aminobutyraldehyde diethylacetal 20, which was protected 
with benzyl chloroformate followed by di-tert-butyl dicarbonate to afford 21 (Scheme 
4.3). The acetal in 21 was removed with pyridinium p-toluenesulfonate to provide the 
aldehyde. Treatment of the aldehyde with (benzenesulfonylmethyl)phosphonic acid 
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diethyl ester in presence of NaH followed by deprotection provided the vinyl sulfone 22. 
Treatment of 22 with AD-mix-α afforded the hemiaminal B, Horner-Wadsworth-
Emmons olefination of the hemiaminal followed by treatment with BF3·OEt2 gave the 
piperidine 23. The hydroxyl group in 23 was protected as the benzyl ether to afford 
piperidine 24. Bromination of the ketone in 24 (TMSOTf, DIPEA then NBS) followed by 
treatment of the crude bromoketone with 4-hydroxyquinazoline provided the protected 
febrifugine derivative 11. Deprotection of 11 (HCl) and subsequent neutralization 
provided (+)-febrifugine (12 steps from 20, 8.8% overall yield). 
 
Scheme 4.3. Synthesis of (+)-febrifugine by Evans. 
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4.3 Results and Discussion 
We decided to develop a synthesis of febrifugine that would proceed through a 
precursor that could also be converted into halofuginone and, potentially, other heteroaryl 
linked piperidines by simple coupling with a suitable heterocycle. Retrosynthetically, the 
common precursor to 1 or 2 is a suitably protected piperidinyl bromoketone
3j
 such as C 
(Figure 4.2) which derives from the functionalized piperidinone D. The piperidinone D 
can be obtained by isomerization
9
 of an amino alkyl lactone such as E. Ultimately, E 
derives from the functionalized butenolide F which leads to the organocatalytic direct 
vinylogous aldol reaction
10
 of crotonolactone and an appropriate aldehyde. The 
vinylogous aldol reaction
11
 directly sets the absolute stereochemistry at C-5 in the 
piperidine ring of the target. The stereochemistry at C-6 is indirectly controlled by the 
aldol reaction and is achieved by manipulation of the secondary alcohol stereocenter in 
the aldol adduct (Figure 4.2). 
 
 
Figure 4.2. The organocatalytic direct vinylogous aldol route to febrifugine. 
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Our investigations began with the synthesis of 28 (Scheme 4.4). Initially, the 
direct vinylogous aldol reaction of commercially available γ-crotonolactone 26 and the 
aldehyde 27
12
 was examined in the presence of selected cyclohexanediamine, 
diphenylethylenediamine and cinchonidine derived thioureas
13
 (25a, 25b, 25c) and 
cyclohexanediamine and diphenylethylenediamine derived squaramides
14
 (25d and 25e, 
Figure 4.3).  
 
Figure 4.3. Selected aminothiourea and aminosquaramide catalysts. 
 
Orienting experiments with the catalyst 25a suggested dichloromethane as a 
solvent for further studies based on the yield and enantiomeric excess of 28 (Table 4.1, 
entries 1-4). Although lowering the temperature (0 
o
C) increased the diastereoselectivity 
and enantiomeric excess for 28, the reaction was prohibitively slow (Table 4.1, entry 5, 
8% yield of 28). The diphenylethylenediamine-derived aminothiourea 25b was 
ineffective as a catalyst and provided only a trace of 28 in dichloromethane (Table 4.1, 
entries 6-8). Catalyst 25c provided 28 in low yield and moderate enantiomeric excess 
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(Table 4.1, entry 9). Reactions with the aminosquaramide catalysts 25d and 25e were 
slower, but provided 28 with higher enantiomeric excess (Table 4.1, entries 10-16) than 
the aminothiourea catalysts 25a-c. For catalyst 25d, the use of dichloromethane as the 
solvent provided the highest enantiomeric excess (Table 4.1, entries 10-12) but the yield 
and diastereostelectivity for 28 remained low. Further studies with the aminosquaramide 
catalyst 25e
14a
 in ethyl acetate provided 28 with good enantiomeric excess (95%) but low 
diastereoselectivity and yield. In comparison, the reaction with 25e was synthetically 
more useful when dichloromethane was used as the solvent (Table 4.1, entries 14-16). 
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Entry
a
 Cat
b
 
 
Solvent T/h Yield (%) dr
c
 (anti/syn) ee
d
 (%) (anti)
e
 
1 25a CH2Cl2 24 59 1.1/1 −55 
2 25a toluene 24 68 1/1 −18 
3 25a EtOAc 24 31 1.1/1 −58 
4 25a DMF 24 12 1/1 −30 
5 25a CH2Cl2 144
f
 8 4.2/1 −62 
6 25b CH2Cl2 144 2 - −61 
7 25b EtOAc 144 0 - - 
8 25b toluene 144 0 - - 
9 25c CH2Cl2 48 13 1.5/1 −74 
10 25d CH2Cl2 48 31 1.9/1 −90 
11 25d CH2Cl2 144
f
 16 2.2/1 −93 
12 25d EtOAc 48 20 1.6/1 −88 
13 25d toluene 48 39 1.5/1 −88 
14 25e EtOAc 120 18 2.4/1 95 
15 25e CH2Cl2 192 74 8/1 91 
16 25e toluene 120 27 2.9/1 90 
a
2 equiv. of crotonolactone. 
b
20 mol%. 
c 1
H NMR of crude products. 
d
Chiral HPLC 
analysis. 
e‘−ee’ indicates formation of the enantiomer of 28   fReaction at 0 oC 
 
Table 4.1. Optimization of the ODVA reaction of crotonolactone and aldehyde 27. 
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Thus the direct vinylogous aldol reaction of γ-crotonolactone with the aldehyde 
27 using 25e as the catalyst provided the butenolide 28 in good yield and 
diastereoselectivity (74%, anti/syn = 8/1) and excellent enantiomeric excess (er = 19/1 for 
the anti diastereomer) when the reaction was conducted in dichloromethane (Scheme 
4.4). Following the planned synthetic strategy (Figure 4.2), it may be noted that the 2,3-
trans substitution in the target piperidine can be obtained only from the anti diastereomer 
of the corresponding amino butyrolactone (Figure 4.2, E). Since our approach to this 
amino lactone would involve an invertive amination of the precursor alcohol, a switch of 
the aldol product stereochemistry from the anti to the syn isomer is required. For this, 28 
was first hydrogenated and then Mitsunobu inversion of the secondary alcohol was 
examined under a variety of conditions. These attempts invariably led to complex 
mixtures and hence an alternate strategy for alcohol inversion became necessary. 
Accordingly, the alcohol was first oxidized to provide the ketolactone 29. Reduction of 
29 with K-Selectride
®
 gave syn-30 (70%) with good diastereoselectivity (syn/anti = 16/1, 
presumably via the Felkin-Anh model,
15
 G, Scheme 4.4).
16
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Scheme 4.4. Synthesis of syn-alcohol 30 via ODVA reaction. 
 
The stereochemical assignments for 28 were based on our earlier studies of the 
organocatalytic vinylogous aldol reaction of γ-crotonolactone in which aromatic 
aldehydes provided the anti aldol as the major product (Chapter 2, pages 34-36). For the 
anti and syn assignments in the present study, the trend in chemical shifts of the methine 
protons (CH-O) in these aldol products were compared with those observed for 28 (see 
ref. 10d). The formation of (+)-febrifugine in the present study confirms the absolute 
configuration of 28. 
The lactone 30 was readily converted into the azido lactone 31 (mesylation and 
azidation with inversion) with the required anti stereochemistry (anti/syn = 16/1, Scheme 
4.5). Reduction of the azide (H2, Pd/C) generated a mixture of the corresponding amino 
butyrolactone and the required piperidone 32 obtained from the intramolecular N-
acylation of the amino lactone. Notably, hydrogenation of 31 in the presence K2CO3 
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significantly facilitated this rearrangement to directly provide 32 (80% from 30) without 
any residual amino lactone. Reduction of the lactam in 32 provided the corresponding 
piperidine 33 which was isolated as a single diastereomer, presumably due to enrichment 
of the trans isomer during the reduction and isolation. N-protection of the piperidine 33 
as carbobenzyloxy followed by protection of hydroxyl group as benzyl ether to provide 
the key intermediate 34 (71% from 32, Scheme 4.5). 
 
 
Scheme 4.5. Synthesis of piperidine  34. 
 
With the piperidine 34 in hand, the final steps of the synthesis were initiated. The 
ketone in 34 was unmasked by treatment of the ketal with iodine in acetone to provide 24 
(Scheme 4.6). Comparison of the spectral data of 24 with reported values
3a,i
 confirmed 
the trans orientation of the substituents on the piperidine ring. This also confirms the 
initial stereochemical assignments for 28. Bromination of the ketone in 24 was achieved 
by the procedure reported by Honda (TMSOTf, DBU then NBS)
3i
 and the crude 
bromoketone was reacted with 4-hydrazoquinazoline to provide the protected febrifugine 
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derivative 11. Deprotection of 11 (6 N HCl) and subsequent neutralization provided (+)-
febrifugine. ([α]D
23
 = +17.7 (c 0.6, EtOH); lit.
3a
 [α]D
25
 = +14.6 (c 1.0, EtOH), 86% ee). 
 
 
Scheme 4.6. Total synthesis of (+)-febrifugine. 
 
4.4 Conclusions 
In conclusion, a stereoselective synthesis of (+)-febrifugine (14 steps, 6.8% 
overall yield) was achieved by employing an organocatalytic asymmetric direct 
vinylogous aldol reaction of γ-crotonolactone and the isomerization of a 2-aminoalkyl 
furanone to the 2,3-disubstituted piperidine core of the target as the key steps. Since the 
bromoketone obtained from 24 can be converted into (+)-halofuginone by coupling with 
7-bromo-6-chloro-4-hydroxyquinazoline,
3a
 the present study also constitutes a formal 
synthesis of (+)-halofuginone. 
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4.5 Experimental section 
All commercially available reagents were used without purification. All reactions 
requiring anhydrous conditions were performed under an atmosphere of dry nitrogen 
using oven dried glassware. Dichloromethane and tetrahydrofuran were distilled from 
CaH2 and sodium/benzophenone respectively. Commercial precoated silica gel plates 
were used for TLC. Silica gel for column chromatography was 230-400 mesh. All 
melting points are uncorrected. Optical rotations were measured at the sodium D line on a 
digital polarimeter at ambient temperature. 
 
 (S)-5-[(R)-1-Hydroxy-2-(2-methyl-1,3-dioxolan-2-yl)ethyl]furan-2(5H)-one (28): 
 
A mixture of the catalyst 25e (20 mol %, 1.17 g), the aldehyde 27 (1.40 g, 10.8 mmol) 
and 2-(5H)-furanone 26 (1.50 mL, 21.5 mmol) in dichloromethane (10.0 mL) was stirred 
for 192 h at ambient temperature. The mixture was diluted with ethyl acetate (100 mL), 
filtered and the filtrate was concentrated. The residue was purified by flash 
chromatography (CH2Cl2/EtOAc, 10/1) to provide 1.73 g (74%) of 28 as a pale yellow 
solid (anti/syn = 8/1 as determined by 
1
H NMR analysis of the crude product).  
IR (neat): 3467, 2988, 2889, 1795, 1748, 1378, 1163, 1104, 1034, 826 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3): Anti diastereomer: δ 7.67 (dd, 1H, J = 5.8, 1.5 Hz), 6.18 (dd, 1H, J 
= 5.8, 1.9 Hz), 4.85 (dt, 1H, J = 7.0, 1.7 Hz), 4.04-3.99 (m, 4H), 3.88 (ddd, 1H, J = 10.1, 
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7.0, 2.0 Hz), 3.83 (s, 1H), 2.18 (dd, 1H, J = 14.6, 1.9 Hz), 1.95-1.89 (m, 1H), 1.37 (s, 
3H); Visible resonances for the syn diastereomer: δ 7.52 (dd, 1H, J = 5.7, 1.5 Hz), 6.19 
(part of dd, 1H), 5.04-5.02 (m, 1H), 4.28-4.25 (m, 1H); 
13
C NMR (75 MHz, CDCl3): Anti 
diastereomer: δ 172.8, 154.9, 122.1, 110.0, 85.2, 69.6, 64.7, 64.3, 41.4, 24.1; Visible 
resonances for the syn diastereomer: δ 172.9, 153.8, 122.7, 109.8, 84.9, 67.4, 64.8, 
64.3, 40.1, 24.0; MS (APCI, pos.): m/z 215.1 (M+1); HRMS (CI): 215.0915 (215.0919 
calcd for C10H15O5 (M+H)); Rf = 0.30 (EtOAc/hexanes, 4/1); Ee: 90% (anti); HPLC: 
Chiralpak AS-H, hexanes/2-propanol 92/8, 210 nm, anti 28: 42.4 min (minor), 76.7 min 
(major); syn 28: 57.9 min (major), 83.1 min (minor). In repeated runs anti 28 was 
obtained in 89-93% ee. 
 
(S)-5-[(R)-1-Hydroxy-2-(2-methyl-1,3-dioxolan-2-yl)ethyl]dihydrofuran-2(3H)-one 
(28a): 
 
Pd/C (10%, 340 mg) was added to a stirred solution of 28 (1.70 g, 7.93 mmol) in 
methanol (80.0 mL). The mixture was stirred for 16 h at ambient temperature under a 
balloon filled with H2 and then filtered through a pad of Celite. The filter cake was 
washed with methanol (2 x 30 mL) and the combined filtrates were concentrated under 
reduced pressure to provide 1.70 g (99%) of (S)-dihydro-5-[(R)-1-hydroxy-2-(2-methyl-
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1,3-dioxolan-2-yl)ethyl]furan-2(3H)-one 28a as a white solid (anti/syn = 8/1). This was 
pure (
1
H NMR) and was directly used in the next step. 
IR (neat): 3500, 2985, 2892, 1770, 1658, 1567, 1549, 1459, 1377, 1278, 1190, 1171, 
1119, 1027, 996 cm
-1
; 
1
H NMR (500 MHz, CDCl3): Anti diastereomer: δ 4.37-4.32 (m, 
1H), 4.06-3.99 (m, 5H), 3.58 (br s, 1H), 2.60 (ddd, 1H, J = 17.8, 9.4, 6.4 Hz), 2.53-2.48 
(m, 1H), 2.28-2.23 (m, 1H), 2.01 (dd, 1H, J = 14.6, 2.0 Hz), 1.81 (dd, 1H, J = 14.6, 10.0 
Hz), 1.38 (s, 3H); Visible resonances for the syn diastereomer: δ 4.43-4.40 (m, 1H), 
2.68-2.64 (m, 1H), 2.46-2.45 (m, 1H), 2.08 (dd, 1H, J = 14.9, 10.5 Hz), 1.87 (dd, 1H, J = 
14.8, 1.8 Hz), 1.37 (s, 3H);
 13
C NMR (75 MHz, CDCl3): Anti diastereomer: δ 177.2, 
110.0, 82.3, 69.1, 64.8, 64.3, 40.9, 28.3, 24.2, 22.8; Visible resonances for the syn 
diastereomer: δ 177.9, 109.9, 82.4, 69.8, 68.5, 64.8, 40.8, 28.3, 24.0, 23.9; MS (APCI, 
pos.): m/z 217.1 (M+1); HRMS (CI): 217.1072 (217.1076 calcd for C10H17O5 (M+H)); Rf 
= 0.30 (EtOAc/hexanes, 3/2). 
 
(S)-5-[2-(2-methyl-1,3-dioxolan-2-yl)acetyl]dihydrofuran-2(3H)-one (29): 
 
To a solution of the above alcohol 28a (900 mg, 4.16 mmol) in CH2Cl2 (30.0 mL) was 
added Dess-Martin periodinane (3.53 g, 8.32 mmol) and the mixture was stirred at room 
temperature for 16 h. Saturated aqueous sodium bicarbonate (30 mL) was added, the 
organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 x 30 
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mL). The combined organic layers were washed with brine (30 mL), dried (Na2SO4), and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc, 1/1) to 
provide 714 mg (80%) of 29 as a pale yellow liquid. 
IR (neat): 2996, 2893, 1769, 1718, 1373, 1252, 1153, 1043, 995, 947, 874 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3): δ 4.91-4.88 (m, 1H), 3.99-3.95 (m, 4H), 3.09 (d, 1H, J = 13.4 Hz), 
2.88 (d, 1H, J = 13.4 Hz), 2.55-2.45 (m, 3H), 2.38-2.33 (m, 1H), 1.44 (s, 3H); 
13
C NMR 
(75 MHz, CDCl3): δ 205.0, 176.3, 108.0, 82.2, 64.8, 64.7, 47.5, 27.3, 24.7, 24.2; MS 
(APCI, pos.): m/z 215.1 (M+1), [α]D
23
 = +18.8 (c 0.92, CHCl3); HRMS (CI): m/z 
214.0808 (214.0841 calcd for C10H14O5); Rf = 0.30 (EtOAc/hexanes, 1/1). 
 
(S)-5-[(S)-1-Hydroxy-2-(2-methyl-1,3-dioxolan-2-yl)ethyl]furan-2(5H)-one (30): 
 
K-Selectride
®
 (1.0 M in THF, 2.80 mL, 2.80 mmol) was added to a stirred solution of the 
ketone 29 (400 mg, 1.86 mmol) in THF (2.0 mL) at -78 
o
C and the mixture was stirred at 
-78 
o
C for 1 h. Saturated aqueous ammonium chloride solution (15 mL) was added 
followed by EtOAc (20 mL). The organic layer was separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were dried (Na2SO4), 
and concentrated. The residue was purified by flash chromatography (hexanes/EtOAc, 
1/1) to provide 283 mg (70%) of 30 as a colorless liquid (syn/anti = 16/1). 
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IR (neat): 3498, 2986, 2960, 2933, 2890, 1765, 1378, 1260, 1167, 1110, 1038, 913, 845 
cm
-1
;
 1
H NMR (500 MHz, CDCl3): Syn diastereomer: δ 4.44-4.39 (m, 1H), 4.02-4.01 
(m, 4H), 4.00-3.95 (m, 1H), 3.57 (br s, 1H), 2.74-2.63 (m, 1H), 2.50-2.39 (m, 1H), 2.31-
2.25 (m, 2H), 2.15-2.02 (m, 1H), 1.87 (dd, 1H, J = 14.8, 1.8 Hz), 1.38 (s, 3H); Visible 
resonances for the anti diastereomer: δ 4.43-4.40 (m, 1H), 2.68-2.64 (m, 1H), 1.87 (dd, 
1H, J = 14.6, 2.0 Hz), 1.37 (s, 3H);
 13
C NMR (75 MHz, CDCl3): Syn diastereomer: δ 
177.9, 109.9, 82.4, 69.8, 64.8, 64.3, 40.8, 28.3, 24.1, 23.9; Visible resonances for the 
anti diastereomer: δ 177.2, 110.0, 82.2, 69.1, 64.8, 40.9, 28.3, 24.2, 22.8;  MS (APCI, 
pos.): m/z 217.1 (M+1); HRMS (CI): 217.1072 (217.1076 calcd for C10H17O5 (M+H)); Rf 
= 0.30 (EtOAc/hexanes, 3/2). 
 
(S)-5-[(R)-1-Azido-2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-dihydrofuran-2(3H)-one 
(31): 
 
To a solution of 30 (600 mg, 2.77 mmol) in CH2Cl2 (10.0 mL) at 0 
o
C under nitrogen was 
added triethylamine (463 µL, 3.32 mmol) followed by methanesulfonyl chloride (259 µL, 
3.32 mmol). The mixture was stirred for 1 h at 0 
o
C and water was added at 0 
o
C. The 
mixture was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were dried 
(Na2SO4) and concentrated to provide 810 mg (99%) of the mesylate as a yellow oil. This 
was used immediately in the next step without purification. 
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Sodium azide (822 mg, 12.6 mmol) was added to a solution of the crude mesylate (744 
mg, 2.53 mmol) in DMF (8.0 mL) and the mixture was stirred at 80 
o
C for 96 h under N2. 
The mixture was cooled to room temperature and EtOAc (30 mL) was added followed by 
water (30 mL). The resulting biphase was separated and the aqueous layer was extracted 
with EtOAc (2 x 30 mL). The combined organic layers were dried (Na2SO4), filtered and 
concentrated to provide 610 mg (quant.) of 31 as a yellow oil (anti/syn = 16/1). This was 
pure (
1
H NMR) and was directly used in the next step. An analytical sample (anti/syn = 
25/1) was obtained by flash column chromatography on silica gel (hexanes/EtOAc, 7/3). 
IR (neat): 2987, 2959, 2923, 2852, 2108, 1772, 1462, 1378, 1255, 1186, 1144, 1029, 948 
cm
-1
; 
1
H NMR (500 MHz, CDCl3): Anti diastereomer:  δ 4.56-4.4.52 (m, 1H), 4.04-3.96 
(m, 4H), 3.94-3.91 (m, 1H), 2.63 (ddd, 1H, J = 17.9, 10.2, 5.5 Hz), 2.55-2.48 (m, 1H), 
2.27-2.19 (m, 1H), 2.15-2.07 (m, 1H), 1.94 (dd, 1H, J = 14.9, 7.3 Hz), 1.88 (dd, 1H, J = 
14.9, 4.5 Hz), 1.37 (s, 3H); Visible resonances for the syn diastereomer: δ 4.60-4.57 
(m, 1H), 3.58-3.54 (m, 1H), 1.39 (s, 3H);
 13
C NMR (75 MHz, CDCl3): Anti 
diastereomer: δ 176.5, 108.1, 80.9, 64.7, 64.5,  60.5, 39.3, 28.2, 24.3, 22.2; Visible 
resonances for the syn diastereomer: δ 176.4, 108.2, 81.8, 64.64, 64.61,  60.5, 39.2, 
28.1, 24.5, 22.4; MS (CI pos.): m/z 242.1 (M+1); HRMS (APCI pos.): m/z 242.1145 
(242.1141 calcd for C10H16N3O4 (M+H)); Rf = 0.50 (EtOAc/hexanes, 3/2). 
 
 
 
 
 150 
 
(5S,6R)-5-Hydroxy-6-[(2-methyl-1,3-dioxolan-2-yl)methyl]piperidin-2-one (32): 
 
To a stirred solution of the azide 31 (281 mg, 1.16 mmol) in methanol (5.0 mL) at 
ambient temperature was added K2CO3 (56 mg, 20%) followed by Pd/C (10%, 56 mg). 
The mixture was stirred for 16 h at ambient temperature under a balloon filled with H2 
and then filtered through a pad of Celite. The filter cake was washed with MeOH (2 x 20 
mL) and the combined filtrates were concentrated under reduced pressure to provide a 
yellow gum. This was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 
19/1) to provide 200 mg (80%) of 32 as a white solid (trans/cis = 17/1). The overall yield 
of 32 (from 30) is 80%. 
IR (neat): 3352, 3229, 1633, 1464, 1420, 1384, 1255, 1215, 1173, 1129, 1064, 1029, 988, 
947, 902, 855   cm
-1
, 
1
H NMR (500 MHz, CDCl3): Trans diastereomer: 6.63 (br s, 1H), 
4.01-3.97 (m, 4H), 3.56 (br t, 1H, J = 9.5 Hz), 3.43-3.39 (m, 1H), 2.86 (br s, 1H), 2.49 
(ddd, 1H, J = 18.0, 6.2, 3.4 Hz), 2.38 (ddd, 1H, J = 17.9, 11.4, 6.4 Hz), 2.32 (dd, 1H, J = 
14.5, 2.1 Hz), 2.08-2.03 (m, 1H), 1.89-1.83 (m, 1H), 1.73 (dd, 1H, J = 14.5, 9.8 Hz), 1.35 
(s, 3H); Visible resonances for the cis diastereomer:
 
6.47 (s, 1H), 3.67-3.64 (m, 1H), 
2.01-1.99 (m, 1H); 
13
C NMR (75 MHz, CDCl3): Trans diastereomer: δ 170.9, 109.7, 
68.9, 64.7, 64.3, 55.5, 41.8, 29.1, 29.0, 24.0; Visible resonances for the cis 
diastereomer: δ 171.5, 109.4, 65.7, 64.6, 53.1, 40.5, 27.6, 25.8, 24.2; MS (APCI, pos.) 
m/z 216.1 (M+1); HRMS (CI): 216.1235 (216.1236 calcd for C10H18NO4 (M+H)); Rf = 
0.25 (CH2Cl2/MeOH, 4/1). 
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(2R,3S)-Benzyl-3-hydroxy-2-[(2-methyl-1,3-dioxolan-2-yl)methyl]piperidine-1-
carboxylate (33): 
 
To a stirred suspension of LiAlH4 (101 mg, 2.66 mmol) in THF (5.0 mL) was added 32 
(0.19 g, 0.88 mmol) dissolved in THF (5.0 mL) and the mixture was heated to reflux for 
24 h. The mixture was cooled to 0 
o
C, water (0.50 mL) was added slowly and the mixture 
was stirred for 20 min. at room temperature. Sodium sulfate (1.0 g) was added to the 
mixture and it was stirred for 10 min. The mixture was then filtered through a pad of 
Celite. The filter cake was washed with EtOAc (3 x 20 mL) and the combined filtrates 
were concentrated under reduced pressure to provide 160 mg (90%) of (2R,3S)-2-((2-
Methyl-1,3-dioxolan-2-yl)methyl)piperidin-3-ol 33 as a white solid. This was exclusively 
the trans diastereomer (500 MHz 
1
H NMR) and was used in the next step without 
purification. 
IR (neat): 3316, 3122, 2928, 2862, 2824, 1439, 1374, 1252, 1117, 1086, 1036, 958 cm
-1
;    
1
H NMR (500 MHz, CDCl3):  δ 4.01-3.96 (m, 4H), 3.20 (ddd, 1H, J = 13.1, 8.7, 4.4 Hz), 
2.96-2.92 (m, 1H), 2.55 (td, 1H, J = 11.8, 2.7 Hz), 2.49 (ddd, 1H, J = 11.0, 7.3, 3.7 Hz), 
2.23 (dd, 1H, J = 14.8, 3.7 Hz), 2.09-2.04 (m, 1H), 1.72 (dd, 1H, J = 14.8, 7.2 Hz), 1.68-
1.66 (m, 1H), 1.54-1.50 (m, 1H), 1.38 (s, 3H), 1.35-1.27 (m, 1H); 
13
C NMR (75 MHz, 
CDCl3): δ 110.1, 72.2, 64.6, 64.4, 59.9, 46.1, 42.2, 34.2, 25.4, 24.1; MS (APCI, pos.): m/z 
202.1 (M+1); HRMS (CI): 200.1287 (200.1287 calc. for C10H18NO3 (M-H)), 202.1444 
(202.1443 calcd for C10H20NO3 (M+H)); Rf = 0.30 (CH2Cl2/MeOH, 4/1). 
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(2R,3S)-Benzyl 3-hydroxy-2-[(2-methyl-1,3-dioxolan-2-yl)methyl]piperidine-1-
carboxylate (33a): 
 
To a solution of the above amino alcohol 33 (0.16 g, 0.79 mmol) in CH2Cl2 (10.0 mL) 
were added benzylchloroformate (0.11 mL, 0.79 mmol), and triethylamine (0.13 mL, 
0.95 mmol) at 0 
o
C. The solution was stirred at room temperature for 16 h, water (10 mL) 
was added and the resulting mixture was extracted with CH2Cl2 (2 x 20 mL). The 
combined organic layers were dried (Na2SO4) and concentrated. Purification of the 
residue by flash chromatography on silica gel (hexanes/EtOAc, 2/3) provided 243 mg 
(91%) of 33a as colorless oil.  
IR (neat): 3467, 2940, 2880, 1672, 1428, 1352, 1257, 1153, 1117, 1077, 1033, 983 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.38-7.28 (m, 5H), 5.15 (s, 2H), 4.49 (br s, 1H), 4.07 (br 
s, 1H), 3.90-3.88 (br m, 5H), 2.89 (br m, 1H), 1.98-1.83 (m, 2H), 1.80 (dd, 1H, J = 14.6, 
6.1 Hz), 1.74-1.68 (m, 3H), 1.45-1.35 (br m, 1H), 1.32 (br s, 3H);
 13
C NMR (75 MHz, 
CDCl3): δ 156.3, 136.9, 128.4, 127.9, 127.8, 109.0, 68.2, 67.2, 64.54, 64.50, 54.0, 39.1, 
38.2, 25.7, 23.9, 19.1; MS (APCI, pos.): m/z 336.2 (M+1); HRMS (CI): 336.1813 
(336.1811 calcd for C18H26NO5 (M+H)); [α]D
23
 = −20.9 (c 0.38, CHCl3); Rf = 0.30 
(EtOAc/hexanes, 3/2). 
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(2R,3S)-Benzyl-3-(benzyloxy)-2-[(2-methyl-1,3-dioxolan-2-yl)methyl]piperidine-1-
carboxylate (34): 
 
To a solution of the above carbamate 33a (80 mg, 0.24 mmol) in THF (3.0 mL) under N2 
at room temperature was added potassium hydride (30% dispersion in mineral oil, 32 mg, 
0.24 mmol) followed by benzyl bromide (29 µL, 0.24 mmol) at ambient temperature. The 
mixture was stirred at ambient temperature for 2 h, cooled to 0 
o
C and water was added. 
The resulting mixture was extracted with EtOAc (2 x 10 mL). The combined organic 
layers were dried (Na2SO4) and concentrated. The residue was purified by flash 
chromatography on silica gel (hexanes/EtOAc, 1/1) to give 87 mg (86%) of 34 as 
colorless oil. 
IR (neat): 2930, 2881, 1692, 1423, 1351, 1255, 1200, 1157, 1090, 1045, 1025, 946 cm
-1
; 
1
H NMR (500 MHz, CDCl3): Major rotamer: δ 7.34-7.24 (m, 10H), 5.11-5.07 (AB 
system, 2H, J = 12.4 Hz), 4.69 (t, 1H, J = 5.6 Hz), 4.54 (d, 1H, J = 12.2 Hz), 4.43 (d, 1H, 
J = 12.2 Hz), 4.17 (dd, 1H, J = 13.5, 3.5 Hz), 3.91-3.82 (m, 3H), 3.74-3.72 (m, 1H), 3.50-
3.46 (m, 1H), 2.85 (td, 1H, J = 13.5, 2.9 Hz), 2.04-1.82 (m, 3H), 1.78-1.73 (m, 1H), 1.70-
1.62 (m, 2H), 1.25 (s, 3H); Visible resonances for the minor rotamer: δ 5.19-5.14 (AB 
system, 2H, J = 12.6 Hz), 4.88 (t, 1H, J = 5.8 Hz), 4.73 (d, 1H, J = 12.0 Hz), 4.47 (d, 1H, 
J = 12.0 Hz), 4.06 (dd, 1H, J = 13.4, 3.4 Hz), 3.54-3.52 (m, 1H), 2.91 (td, 1H, J = 13.6, 
2.8 Hz), 1.36 (s, 3H); 
13
C NMR (75 MHz, CDCl3): Major rotamer: δ 155.9, 138.9, 
137.0, 128.3, 128.2 (2C), 127.9, 127.7, 127.1, 109.1, 74.5, 69.8, 67.1, 64.5, 64.4, 49.8, 
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39.1, 38.4, 24.1, 24.0, 19.6; Visible resonances for the minor rotamer: δ 155.7, 137.3, 
128.4, 127.7, 127.6, 127.3, 109.2, 75.7, 70.1, 66.8, 64.6, 64.4, 48.9, 39.2, 38.0, 24.6, 24.0, 
19.9; MS (APCI, pos.): m/z 426.2 (M+1); HRMS (CI): 426.2284 (426.2280 calcd for 
C25H32NO5 (M+H)); [α]D
23
 = −12.4 (c 0.48, CHCl3); Rf = 0.60 (EtOAc/hexanes, 1/1). 
 
(2R,3S)-Benzyl 3-(benzyloxy)-2-(2-oxopropyl)piperidine-1-carboxylate (24): 
 
To a solution of 34 (64 mg, 0.15 mmol) in acetone (2.0 mL) was added a solution of 
iodine (1 mg, 7.8 x 10
-2
 mmol, 5 mol%) in acetone (1.0 mL) at room temperature. The 
solution was stirred at ambient temperature for 30 min and then concentrated. The residue 
was dissolved in CH2Cl2 (10 mL) and aq. 5% Na2S2O3 (5 mL) was added. The biphase 
was stirred vigorously for a few minutes and the organic layer was separated. The 
aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were 
dried (Na2SO4), filtered and concentrated. The residue was purified by flash 
chromatography on silica gel (hexanes/EtOAc, 7/3) to provide 48 mg (84%) of 24 as 
colorless oil.  
IR (neat): 2943, 2866, 1689, 1422, 1355, 1254, 1200, 1132, 1050, 959, 737, 697 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3): δ 7.32-7.25 (m, 10H), 5.15-5.09 (AB system, 2H, J = 12.5 
Hz), 5.01 (br s, 1H), 4.65 (br s, 1H,), 4.51 (d, 1H, J = 12.0 Hz), 4.13 (br s, 1H), 3.44 (br s, 
1H), 2.84 (br s, 1H), 2.69-2.58 (m, 2H), 2.11 (br s, 3H), 1.94-1.85 (m, 2H), 1.65-1.59 (m, 
1H), 1.40 (br d, 1H, J = 11.8 Hz); 
13
C NMR (75 MHz, CDCl3): δ 205.9, 155.9, 138.6, 
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136.8, 128.4, 128.3, 127.9, 127.8, 127.5, 127.4, 73.3, 70.2, 67.2, 49.7, 43.7, 39.5, 30.0, 
24.4, 19.5; HRMS (CI): m/z 382.2021 (382.2018 calcd for C23H28NO4 (M+H)); [α]D
23
 = 
−29.2 (c 1.0, CHCl3); lit.
3a
 [α]D
25
 = −26.8 (c 1.0, CHCl3) for 24 with 86% ee
3a
; Rf = 0.25 
(hexanes/EtOAc, 7/3). The 
1
H NMR and 
13
C NMR data is in agreement with reported 
data.
3a,3i
  
 
(2R,3S)-3-Benzyloxy-2-[2-oxoquinazolin-3(4H)-yl)propyl]piperidine-1-carbamic acid 
benzyl ester (11): 
 
To a solution of 24 (40 mg, 0.11 mmol) in anhydrous CH2Cl2 (2.0 mL) at 0 
o
C was added 
TMSOTf (40 µL, 0.22 mmol) and DIPEA (42 µL, 0.24 mmol). The resulting mixture was 
stirred at 0 
o
C for 45 min. and NBS (39 mg, 0.22 mmol) was added. The mixture was 
stirred at room temperature for 3h and then poured into water (10 mL). The resulting 
mixture was extracted with EtOAc (2 x 10 mL). The combined organic layers were 
washed with water (10 mL), brine (10 mL), dried (Na2SO4), filtered and concentrated to 
provide the crude bromoketone which was used in the next step without purification.  
To a solution of the bromoketone in anhydrous DMF (1.5 mL) was added anhydrous 
K2CO3 (15 mg, 0.11 mmoles) and 4-hydroxyquinazoline (16 mg, 0.11 mmoles). The 
mixture was stirred at room temperature for 2 h and then poured into water (10 mL). The 
resulting mixture was extracted with EtOAc (2 x 10 mL). The combined organic layers 
were washed with water (10 mL), brine (10 mL), dried (Na2SO4), filtered and 
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concentrated. The residue was purified by flash chromatography on silica gel 
(hexanes/EtOAc, 2/3) to give 27 mg (47%) of 11 as a colorless liquid. 
IR: 1726, 1674, 1610, 1424, 1358, 1257, 1085, 1049, 910 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3): δ 8.27 (dd, 1H, J = 8.0, 1.5), 7.92 (br s, 1H), 7.79-7.73 (m, 2H), 7.52-7.49 (m, 
1H), 7.32-7.26 (m, 10H), 5.17 (d, 1H, J = 12.4 Hz), 5.10 (d, 1H, J = 12.4 Hz), 5.01-4.98 
(m, 1H), 4.94 (br s, 1H), 4.65-4.63 (m, 1H), 4.53 (br d, 1H, J = 11.9 Hz), 4.06 (br s, 1H), 
3.52 (br s, 1H), 2.97 (br s, 1H), 2.86 (dd, 1H, J = 14.7, 8.7 Hz), 2.78 (br dd, 1H, J = 14.7, 
6.1 Hz), 1.94-1.88 (br m, 2H), 1.75 (br s, 1H), 1.70-1.63 (m, 1H), 1.44 (apparent br d, 
1H, J = 12.5 Hz);
 13
C NMR (75 MHz, CDCl3): δ 200.0, 160.9, 156.2, 148.2, 146.5, 138.3, 
136.5, 134.5, 128.5, 128.4, 128.0, 127.8, 127.7, 127.6, 127.5, 127.3, 126.7, 121.8, 73.7, 
70.4, 67.4, 53.9, 50.6, 41.0, 39.6, 24.3, 19.4; MS (APCI pos.): m/z 526.2 (M+1); HRMS 
(EI+): 525.2285 (525.2264 calcd for C31H31N3O5 (M+H)) [α]D
23
 = −24.8 (c 1.7, CHCl3); 
lit. [α]D
25
 = −22.0 (c 1.0, CHCl3)
3m
; Rf = 0.30 (EtOAc); spectroscopic data
3a
 (IR, 
1
H 
NMR, 
13
C NMR) and optical rotation
3m
 for 11 are in agreement with reported data.
3a,3m
  
 
3-(3-[(2R,3S)-3-Hydroxypiperidin-2-yl)-2-oxopropyl]quinazolin-4(3H)-one  
((+)-Febrifugine) (1): 
 
A stirred solution of 11 (17 mg, 0.03 mmol) in aqueous HCl (6 M, 2.0 mL) was heated to 
reflux for 1 h. The solution was then cooled to 0 
o
C and was basified with K2CO3 to 
pH~10. The basic solution was extracted with CHCl3 (3 x 30 mL). The combined organic 
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layers were washed with brine (20 mL), dried (Na2SO4) and concentrated to provide 10 
mg (99%) of crude product. This was purified by flash chromatography on silica gel 
(CHCl3/MeOH, 9/1) to provide 7.5 mg (75%) of (+)-febrifugine as a white solid. 
Mp: 133-136
 o
C; (lit.
1
 mp 135-138 
o
C). IR (neat): 3306, 3052, 2926, 2851, 2687, 1726, 
1669, 1607, 1468, 1361, 1325, 1078, 997 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 8.27 (d, 
1H, J = 7.9 Hz), 7.91 (s, 1H), 7.78-7.71 (m, 2H), 7.54-7.48 (m, 1H), 4.93-4.80 (AB 
system, 2H, J = 17.5 Hz), 3.30-3.26 (m, 1H), 3.11 (dd, 1H, J = 16.0, 4.5 Hz), 2.96 (d, 1H, 
J = 11.9 Hz), 2.88-2.87 (m, 1H), 2.64 (dd, 1H, J = 16.1, 7.5 Hz), 2.58 (dt, 1H, J = 12., 3.0 
Hz), 2.22 (br s, 2H), 2.10-2.06 (m, 1H), 1.74-1.70 (m, 1H), 1.53-1.47 (m, 1H), 1.38-1.30 
(m, 1H). 
13
C NMR (75 MHz, CDCl3): δ 202.7, 161.0, 148.2, 146.4, 134.5, 127.6, 127.4, 
126.8, 121.8, 72.2, 60.2, 54.9, 46.0, 44.0, 34.5, 25.6; MS (APCI pos.): m/z 302.1 (M+1); 
HRMS (CI): m/z 302.1512 (302.1505 calcd for C16H20N3O3 (M+H));  [α]D
23
 = +17.7 (c 
0.6, EtOH), lit.
3a
 [α]D
25
 = +14.6 (c 1.0, EtOH); Rf = 0.20 (CH2Cl2/MeOH/Et3N, 
9.00/0.95/0.05). The 
1
H NMR and 
13
C NMR data is in agreement with reported data.
3a,3i
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4.7 Selected 
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4.8 Selected HPLC chromatograms 
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CHAPTER 5 
Conclusions 
 
5.1 Summary of the thesis 
The organocatalytic direct vinylogous aldol (ODVA) reactions of γ-
crotonolactone with various aromatic aldehydes (Scheme 5.1) were developed. It was 
observed that these reactions were catalyzed by several bifunctional chiral 
aminothioureas and aminosquaramides. A catalyst survey was carried out to find the 
optimal catalyst. Among various thiourea and squaramide catalysts, the squaramide 
catalysts gave the best result, providing the anti diastereomer as the major product. The 
optimized conditions were employed in a study of the scope of the reaction with a variety 
of aldehydes. These investigations indicated that the choice of catalyst 4 or 5 was 
determined by the nature of the aldehyde and high enantioselectivities were obtained by 
proper pairing of the catalyst and aldehyde. Overall, good diastereoselectivities (5-8:1) 
and excellent enantioselectivities (94- >99% ee) were obtained. Chapter 2 of this thesis 
describes details of the development of this method. E. K. Paul contributed to all of the 
synthetic work and was involved in the preparation of the manuscript for publication. 
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Scheme 5.1. The ODVA reaction catalyzed by squaramides 4 and 5. 
 
To demonstrate the synthetic importance of the organocatalytic direct vinylogous 
aldol (ODVA) reactions of γ-crotonolactone with aldehydes, application of the 
methodology in the synthesis of 2,3-disubstituted piperidines such as (+)-L-733,060, (+)-
CP-99,994 and (2S,3R)-3-hydroxypipecolic acid was examined. The substance P receptor 
antagonists (+)-L-733,060 and  (+)-CP-99,994, are associated with a variety of biological 
effects including smooth muscle contraction, neurogenic inflammation and pain 
transmission and (2S,3R)-3-hydroxypipecolic acid, is a component of tetrazomine, an 
antitumor agent and an antibiotic. In this project, ODVA reaction of γ-crotonolactone 
with benzaldehyde as the key step provided an efficient entry into piperidine derivatives 
(Scheme 5.2). The synthesis of (+)-L-733,060 was accomplished in 9 steps from the γ-
crotonolactone (1) in 24.8% overall yield. The synthesis of (+)-CP-99,994 was 
accomplished in 11 steps from the γ-crotonolactone (1) in 16.9% overall yield. The 
synthesis of (2S,3R)-3-hydroxypipecolic acid was accomplished in 10 steps from the γ-
crotonolactone (1) in 28.1% overall yield. The results of this work are presented in 
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Chapter 3 of this thesis. E. K. Paul contributed to all of the synthetic work and was 
involved in the preparation of the manuscript for publication. 
 
 
Scheme 5.2. Synthesis of (+)-L-733,060, (+)-CP-99,994 and (2S,3R)-3-hydroxypipecolic   
                     acid.    
 
In the last project, the ODVA reaction was employed in the total synthesis of the 
antimalarial alkaloid (+)-febrifugine and a formal synthesis of (+)-halofuginone, an 
antimalarial agent (Scheme 5.3). The key steps in the synthesis involve the ODVA 
reaction of γ-crotonolactone with the aldehyde 6 and the isomerization of a 2-aminoalkyl 
furanone to the 2,3-disubstituted piperidinone core 9 of the target. The synthesis of the 
(+)-febrifugine was accomplished in 14 steps from the commercially available γ-
crotonolactone (1) in 6.8% overall yield. The results of this work are presented in Chapter 
4 of this thesis. E. K. Paul contributed to all of the synthetic work and was involved in the 
preparation of the manuscript for publication. 
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Scheme 5.3. Synthesis of (+)-febrifugine and a formal synthesis of (+)-halofuginone  
                     employing the ODVA reaction. 
 
In summary, the thesis work has developed a highly enantioselective, 
organocatalytic direct vinylogous aldol reaction of crotonolactone with aldehydes. This 
methodology was used in the synthesis of various biologically active compounds and 
natural products containing the 2,3-disubstituted piperidine motif. 
 
5.2 Future work 
Although the products of the 2-furanone in ODVA reaction can be converted into 
piperidines, a limitation of the methodology is the need for converting the aldol products 
into the corresponding amino lactone. An attractive alternative to this approach would be 
the direct synthesis of the amino lactones 11 via an organocatalytic vinylogous Mannich 
reaction (Scheme 5.4) of imines 10 with 2-furanone.  
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Scheme 5.4. Organocatalytic direct vinylogous Mannich-type reaction of crotonolactone. 
 
It is anticipated that, the Mannich reaction will be catalyzed by hydrogen bonding 
donor catalysts or by chiral protic acids depending on the nature of the amine used to 
make the imines. 
Alternatively, instead of using a chiral catalyst, chiral imines can be used as 
substrates. In addition, the organocatalytic vinylogous aldol as well as Mannich reactions 
can be examined with a variety of substituted crotonolactones. 
